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Zusammenfassung 
Die Aufklärung der Prozesse, die zur Zusammensetzung des Influenza A Virus führen, ist Be-
standteil für die Bekämpfung dieser Infektionskrankheit. Der Viruspartikel setzt sich aus einer 
Hülle, der darunter liegenden Matrix und dem Genom zusammen. Das Genom ist als Bündel 
aus acht Ribunucleoproteinkomplexen organisiert. Die Hülle besteht aus einer Membran, die 
mit Sphingomyelin und Cholesterol angereichert ist und den darin eingebetteten Membran-
proteinen Hämagglutinin, Neuraminidase und dem Protonenkanal M2. Die unter der Hülle 
liegende Matrix wird von einem einzigen Influenzaprotein formiert: Dem Matrixprotein M1. 
Es spielt eine Schlüsselrolle im Replikationszyklus des Virus in der Zelle. Es interagiert mit 
dem genetischen Material, mit den Membranproteinen und der Lipidmembran der Hülle. 
Die vorliegende Arbeit gibt Auskunft, welche Lipide eine Rolle in der M1-Membran-
Wechselwirkung spielen. Die Liste der identifizierten Lipide umfasst neben dem bereits be-
kannten Phosphatidylserin auch Phosphatidylglycerol und Phosphatidsäure. Verschiedene 
Phosphatidylinositole konnten ebenfalls identifiziert werden. Als stärkster M1 Bindungspart-
ner trat dabei Phosphatidylinositol-4-Phosphat zutage. 
Weitere auf Mutanten basierende Untersuchungen zeigten, dass der membranbindende Be-
reich nicht auf eine einzelne Domäne in M1 festgelegt werden kann. Die N-terminale M1-
Domäne mit ihrem Oberflächen-exponierten, positiv geladenen Areal und die C-terminale 
Domäne interagierten mit Modellmembranen. 
Das Resultat dieser Interaktionen konnte mittels mikroskopischer Untersuchungen an giganti-
schen unilamellaren Vesikeln dokumentiert werden. Für M1 und für eine Mutante, die nur aus 
der N-terminalen M1-Domäne besteht, konnte eine von anderen viralen Proteinen unabhängi-
ge homooligomere Organisation auf der Membran gezeigt werden. Diese M1-Cluster könnten 
während der Zusammensetzung des Viruspartikels als Fundament für die Eingliederung aller 
weiteren viralen Komponenten dienen. 
 
 
 
Schlagworte: Fluoreszenzmikroskopie, Influenza A Matrixprotein M1, Protein-Membran-
Interaktionen, unilamellare Vesikel. 
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Abstract 
Knowledge about the assembly process of the influenza A virus particle is essential for the 
development of effective approaches for prevention and treatment of this virus infection. The 
virus particle consists of an envelope, an underlying matrix, and the encapsulated genome. 
The genetic material is organized as bundle of eight ribonucleoprotein complexes that encode 
for eleven proteins. The envelope consists of a lipid bilayer that is enriched in sphingomyelin 
and cholesterol. The viral spike proteins, hemagglutinin and neuraminidase, as well as the 
proton channel M2 are embedded into this membrane. The matrix can be found below the 
envelope. It is formed by one single protein, the matrix protein M1. M1 plays a crucial role 
during the replication of the virus in the cell. It interacts with the genetic material, with the 
envelope proteins and with the lipid bilayer of the envelope.  
The results of this study reveal in detail which lipids are targeted by M1. The set of identified 
lipids contains phosphatylglycerol and phosphatidic acids as new binding partners, beside the 
known phophatidylserine. Additionally, several phosphatidylinositols were identified. Phos-
phatidylinositol-4-phosphate was the strongest binding partner from this group. 
Mutant-based analysis revealed that M1 owns more than one membrane binding site. The 
positively charged area in the N-terminal and the C-terminal domain mediated membrane as-
sociation of the respective mutant protein. 
The final constitution of M1 on the membrane was characterized by confocal fluorescence 
microscopy on giant unilamellar vesicles. Full length M1 and a mutant that consisted only of 
the N-terminal part of M1 showed lateral clustering of homooligomers on the vesicle surface. 
The clusters formed independently of any other viral component. A function as fundament for 
the incorporation of the other viral components can be assumed for these clusters. 
 
 
 
Keywords: Unilamellar vesicles, influenza matrix protein M1, protein-membrane interaction, 
fluorescence microscopy 
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Abbreviations 
APS Ammonium persulfate 
Aλ Absorption at wavelength λ in nm 
C6-NBD-PC 1-Palmitoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-
sn-glycero-3-phosphatidylcholine 
Chol Cholesterol 
DLS dynamic light scattering 
DOPC Dioleoyl-phosphatidylcholine 
DOPS Dioleoyl-phosphatidylserine 
EDTA Ethylenediaminetetraacetic acid 
FM Fluorescein-5-maleimide 
FRAP Fluorescence recovery after photobleaching 
FRET Förster resonance energy transfer 
GUV giant unilamellar vesicle 
HA Hemagglutinin 
LUV large unilamellar vesicle 
M1 Matrix protein 1 
MOPS 3-(N-morpholino)propanesulfonic acid 
NaP 10 mM sodium phosphate buffer, pH 7 
NaPKCl 10 mM sodium phosphate buffer with 120 mM potassium chloride, pH 7 
Cy-, Cys- Cysteine 
N-NBD-DPPE N-(7-nitrobenzy-2-oxa-l,3-di azol-4-yl)-1,2-dipalmitoyl-sn-glycero-3-
phosphatidylethanolamine 
ODλ optical density at wavelength λ in nm 
ORF open reading frame 
PAGE polyacrylamide gel electrophoresis 
PBS polybasic sequence 
PCR Polymerase chain reaction 
PI3P Phosphatidylinositol-3-phosphate 
PI4P Phosphatidylinositol-4-phosphate 
SDS Sodium dodecyl sulfate 
SM Sphingomyelin 
SUV  small unilamellar vesicle 
Tm melting temperature 
TMR 5/6-Carboxy-tetramethylrhodamine-ethyl-maleimide 
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1 Introduction 
Infection by the influenza virus results in the death of a quarter- to a half-million people an-
nually. In Germany alone 21,959 people died in 2008 [1] from flu-like diseases. In April 2009, 
a highly infectious influenza variant emerged in Mexico and caught world-wide attention. 
This influenza A H1N1 strain, so called “New flu”, spread rapidly and was classified as pan-
demic by the WHO in June 2009 [2]. The fundamental mechanisms governing influenza in-
fection need to be understood in detail to prevent and treat future outbreaks. This effort will 
require both basic and applied medical research, and studies on the molecular level. Bio-
chemical and biophysical methods promise substantial progress in the discovery of the 
mechanisms of influenza virus replication and assembly in the cell.  
1.1 Influenza 
The history of the influenza disease can be traced back to the ancient Greeks. Hippocrates 
described bronchial infections with symptoms similar to influenza [3]. More accurate records 
of influenza pandemics are available since the 16th century. During the following centuries 
several major outbreaks occurred [4] of which the most recent were the Spanish flu with over 
50 million deaths in 1918 [5,6] and the Hong Kong flu 1968 with reported one million deaths 
[7,8].  
Wild aquatic birds are the widely accepted reservoir hosts for influenza viruses [9,10]. Re-
search on avian influenza-based human viruses revealed a two-step transmission mechanism, 
where an avian strain infected an intermediate swine host and was then transmitted to humans 
[11]. Direct transmission between humans and birds has been described for H5N1 virus 
strains between 2003 – 2005 in Asia [11]. In most cases the transmission rates between ani-
mals and humans were low [12]. Pandemic viruses like the H1N1 virus from 2009 were ex-
ceptionally contagious and spread rapidly among humans around the world [13,14]. This par-
ticular H1N1 virus was first detected in Mexico and characterized on the molecular level. It 
contained components of human, avian, and swine specific viruses [13,15].  
The mechanism upon which different viral genes are combined is called re-assortment and 
occurs when different influenza hosts live in close proximity and cross infections occur. Dur-
ing an infection with different viruses, new virus particles are assembled which contain ge-
netic material from both influenza strains [16]. 
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The Influenza A and B genus, together with the genera of Influenza C, Thogotoviruses, and 
the Isavirus belong to the family Orthomyxoviridae. Recently additional viruses have been 
discovered and pooled in a fifth yet unnamed genus [17] which also harbor the major charac-
teristic of the Orthomyxoviridae – the segmented and single-stranded RNA genome of nega-
tive polarity. The individual influenza genera can be distinguished by host range, genome and 
viron structure. Influenza A and B have a similar viron structure and a segmented genome 
consisting of eight pieces which encode 11 proteins in total (see chapter 1.1.1). Influenza C 
has in contrast to A and B only seven genomic segments. The distinction between A and B lies 
in the specificity of the nucleoprotein (NP) which is necessary for the organization of the ge-
nome and also determines the host range [18]. Whereas influenza B causes mostly mild symp-
toms upon infection in humans, pandemics with severe phenotypes are mainly caused by the 
influenza A virus.  
1.1.1 The influenza virus particle 
Influenza virus particles are pleomorphic. Beside spheres with an approximate size of 100 – 
150 nm [19], filamentous particles can also be observed [20]. The envelope of the particles 
consists of a lipid bilayer in which three different membrane proteins are embedded (Figure 
1). The trimeric hemagglutinin (HA) mediates binding to the host membrane and fusion of the 
viral and the target membrane. For influenza A 16 different avian HA subtypes (H1 – H16) 
have been classified by their serological behavior [21,22]. Three HA serotypes (H1, H2, and 
H3) have been found to be adapted to the human population [23]. The second membrane pro-
tein, neuraminidase (NA), is tetrameric and removes the receptor molecules recognized by 
HA from the outer membrane surface. Nine NA serotypes (N1 – N9) have been described 
[22]. The tetrameric protein M2, the third membrane protein, acts as a proton channel. Influ-
enza B particles contain both HA and NA but M2 is replaced by a proton channel named NB 
[24]. In Influenza C the multifunctional hemagglutinin-esterase-fusion protein (HEF) carries 
the activities of HA and NA [18]. The proton channel is formed by the CM2 protein [25]. 
Directly beneath the envelope lies a shell of M1 protein. M1 oligomerization and interactions 
with the membrane as well as with HA, NA and M2 have been postulated as being necessary 
for the formation of this layer [26,27,28]. M1 encloses the virus core that contains the seven 
(influenza C) or eight (influenza A and B) viral ribonucleoprotein (vRNP) complexes [29] 
which carry the genetic material of the virus. Each vRNP complex consists of a single-
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stranded, negatively oriented RNA that is coiled into a panhandle-like structure by oligomer-
ized NP. The polymerase complex with the proteins PB1, PB2, and PA is located at the termi-
nal end of the panhandle [30]. The polymerase complex mediates the transcription of viral 
RNA.  
Two additional proteins complete the particle structure. The multifunctional NS1 protein has a 
modulating effect on the transcription of viral RNA and an enhancing effect on translation of 
viral mRNA [31]. The nuclear export protein (NEP – previously NS2) is responsible for the 
export of newly formed vRNP complexes from the nucleus [32]. 
 
Figure 1 The influenza particle. (A) Model of the Influenza A particle depicting the envelope with the spike pro-
teins hemagglutinin (HA), neuraminidase (NA) and the proton channel M2 embedded into the lipid bilayer. Oli-
gomerized M1 interacts with the envelope components and encloses the viral ribonucleoprotein (vRNP) com-
plexes. Adapted from [33]. (B) Electron micrograph of a spherical and an elongated virus particle with visible 
spike proteins and genomic material in the center [34]. (C) A model of a vRNP [30]. 
1.1.2 Influenza replication cycle 
The replication of influenza can basically be divided into three stages: (i) internalization, (ii) 
production of the viral components, and (iii) assembly and release. Figure 2 summarizes the 
replications cycle. Initially, HA binds to cell surface receptors on the host membrane. These 
receptors are glycoproteins and glycolipids containing oligosaccharides with terminal sialic 
acids. Sialic acids comprise a molecule group based on neuraminic acid with the most com-
mon member being N-acetylneuraminic acid [35]. The precise linkage of the monosaccha-
rides determines the host preference. In case of avian influenza sialic acids are recognized that 
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are bound to galactose through α2-3 linkages [23]. Viruses infecting humans attach to α2-6- 
linked sialic acids [23]. The binding mechanism between HA and the sialic acids carrying 
glycoproteins and glycolipids is modulated by HAs own oligosaccharides. It was shown for 
HA with truncated glycosylations that the receptor binding was increased [36,37]. 
 
Figure 2 Replication cycle of Influenza A. HA binds in a first step to sialic acids on the surface of the host cell. 
The bound virus particle is internalized via receptor-mediated endocytosis. The acidification of the late en-
dosome triggers conformational changes in HA, which lead to fusion of endosomal and viral membrane. The 
vRNPs are released through the fusion pore and transported to the nucleus. Viral mRNA synthesis occurs in the 
nucleus. The viral mRNAs induce production of the viral membrane proteins HA, NA, and M2 at the endoplas-
mic reticulum (ER). These membrane proteins are transported towards the assembly site through the Golgi appa-
ratus. The other proteins are translated on cytoplasmic ribosomes. Early proteins, which are necessary for tran-
scription and vRNP replication and assembly, are imported into the nucleus. Late proteins, like M1 and NS2 
(NEP) enable the export of the vRNPs. When all components are assembled at the plasma membrane the new 
progeny virions bud. Adapted from [38]. 
When the virus is attached to the host membrane the cell internalizes the particle via receptor-
mediated endocytosis. It could be shown that the resulting endosome is produced by clathrin-
dependent and -independent pathways [39,40]. The endosome is transported by the cytoskele-
ton to the interior of the cell in close proximity to the nucleus [41]. Upon formation of the late 
endosome acidification occurs [42]. The lowering of the pH to values of 5.5 - 5 induces a con-
formational change in HA. This leads to the exposition and insertion of HA’s hydrophobic 
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fusion peptide into the host membrane. In a second rearrangement step of HA the host and 
viral membrane are drawn together, resulting in fusion and pore formation (Figure 3) [43,44]. 
 
Figure 3 Conformational changes in hemagglutinin upon endosome acidification. Upon acidification conforma-
tional changes occur in HA (1) that expose the structurally concealed hydrophobic fusion peptide. The fusion 
peptides of the HA trimer insert into the host membrane (2, 3) and in a second rearrangement step the host mem-
brane is drawn into close proximity to the viral membrane (4). Further action of HA leads to membrane fusion 
and the formation of a hemifusion diaphragm (5). Finally, a pore is formed (6). Adapted from [43]. 
Parallel to this, M2 shuttles protons from the endosomal lumen into the viral core. At this 
point M1 plays a crucial role. It functions as a link connecting the cytoplasmic tails of the 
three membrane proteins [26] and the virus membranes [27] to the vRNP complexes [45]. The 
acidification destabilizes the M1 envelope anchor and releases the genome segments into the 
cytoplasm for transport towards the nucleus [46]. The three nuclear localization signals (NLS) 
of NP have been shown to be essential for the import of the vRNP complexes into the nucleus. 
Import has been shown to be mediated by importin α and β and the nuclear pore complex 
[41,47,48]. Within the nucleus the trimeric polymerase complex transcribes the negative-sense 
viral RNA segments into mRNA and replicates them via complementary RNA intermediates 
into abundant copies of vRNA [49,50]. Simultaneously, the mRNAs are exported to the cyto-
plasm or endoplasmatic reticulum (ER) where translation of the eleven influenza proteins 
occurs. HA, NA and M2 are synthesized on the ER from where they are transported via the 
Golgi apparatus to the apical plasma membrane [51]. A co-localization of HA and NA with 
cholesterol- and sphingomyelin-enriched microdomains, so called membrane rafts, was shown 
[52,53,54]; whereas M2 was proposed to be peripherally associated to these liquid ordered 
membrane domains since only a minor portion of M2 was found to be associated with deter-
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gent-resistant membranes [55]. The newly synthesized cytoplasmic proteins M1, NS1, NP, 
and the polymerase subunits are targeted to the nucleus by their intrinsic NLS. In case of NEP 
transport may occur by diffusion [32]. In the cytoplasm the remaining M1 was found to be 
colocalized with cellular membranes including the Golgi vesicles [56,57,58] independent of 
other viral proteins. The PB1-F2 protein, a splicing variant of the polymerase subunit PB1, 
interacts with mitochondrial proteins [59]. In the nucleus, PB1, PB2, PA, and NP together 
with vRNA are assembled into new vRNP complexes. Their export is triggered by a signal 
cascade initiated by the accumulation of HA at the plasma membrane [60]. The single vRNP 
complexes are exported from the nucleus after stepwise association of proteins [61]. First, M1 
attaches to the vRNPs. This association inactivates the polymerase complex and arrests it at 
the terminal part of the vRNP complex [62,63]. NEP binds to M1. It contains a nuclear export 
signal sequence and is the target for the host protein Crm1 [64]. Crm1 facilitates together with 
RanGTP the export of vRNPs through the nuclear pore [65]. The re-import of the complexes 
into the nucleus is inhibited by M1 which possibly shields the NLS of NP [46,66]. Once the 
M1 covered vRNPs are released into the cytoplasm, transport towards the apical plasma 
membrane is mediated by cytoskeleton filaments [62,67]. Assembly of all components into 
the viral particle occurs at the apical plasma membrane, since only there vRNPs are present. 
The current model states that M2 and raft associated HA and NA are linked to each other by 
polymerized M1 that is bound to the cytoplasmic tails of the membrane proteins and to the 
membrane. The observation of the M1 oligomerization process should be experimentally pos-
sible but has not yet been accomplished. Interaction of M1 with membrane proteins and M1 
self-oligomerization [68,69,70] are well studied events, and M1 oligomerization is considered 
essential for membrane bending and formation of the bud involving the cortical actin fila-
ments [71]. The vRNPs are delivered to the budding site and internalized into the bud by pull-
ing into the cavity by envelope-M1 and M1-vRNP interactions and additionally by pushing 
through actin filaments [62]. The mechanism how the single vRNPs are organized in the cy-
toplasm is based on RNA-RNA interaction of specific signal sequences leading to an oc-
tameric super-vRNP [72,73,74]. This complex could be visualized [29] in virus cross-sections. 
The incorporation of the eight vRNPs is not the critical but an essential part of particle forma-
tion. Budding of empty virus-like particles could also be induced in the absence of vRNPs 
[75,76]. The last step is the closure of the bud. Here M2 plays a role in organizing the mem-
brane before pinching-off of the new particle [34,55]. Release of the new particle requires 
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removal of sialic acids from the cell surface. Otherwise the newly synthesized particles re-
main bound on the infected cell. This cleavage is accomplished by NA. The catalytic site of 
NA binds specifically to the sialic acid of the glycoproteins and glycolipids and hydrolyzes 
the linkages to the respective terminal sialic acid [77,78]. 
1.1.3 M1 as key organizer at the membrane level 
Mutational studies showed an essential function of M1 during virus particle formation. Infec-
tious virus production failed when M1 was lacking or when specific amino acid sequences of 
M1 were substituted [79]. An additional hint for the importance of M1 arose when the con-
centration of available M1 was limited. This leads to a delayed and reduced budding of viral 
particles [80]. Even though its role in virus maturation is of such importance, the function of 
M1 during the replication cycle is not understood in detail.  
The 252 amino acids containing matrix protein is encoded on segment seven, the second 
smallest of the eight genome pieces. M1 can be isolated from the virus as a 27.8 kDa protein. 
Its isoelectric point is 9.81. Several attempts have been undertaken to crystallize the protein. 
Sha and Luo [81] presented in 1997 the structure of the N-terminal domain (AA 2 – 158) iso-
lated from virus at pH 4. This structure of wild type M1 revealed an N-terminal subdomain 
formed by the first four helices (H1 – H4). A flexible link including the short helix H5 con-
nects the N-terminal subdomain to the middle subdomain that consists of four additional heli-
ces. The C-terminal structure could not be solved due to proteolysis [81]. Subsequently two 
structures of the same N-terminal part of M1 were published and showed only minor folding 
differences to the structure published by Sha and Luo. Harris et al. as well as Arzt et al. de-
termined the structure at neutral pH [68,82]. Furthermore, the structure of a M1 mutant with 
substituted NLS signal [83] was solved and revealed no structural differences to the wild type. 
Based on the crystal structures, the surface potential of this part of M1 was calculated and 
local concentrations of either positive or negative charged amino acids could be visualized. 
The polybasic sequence (PBS) in H6 that contains the three residues (R101, K104, R105) of 
the NLS motif (101–RKLKR–105) together with K95 and K98 forms a prominent positively 
charged surface area. Beside the function of the NLS as a nuclear sorting signal a function as 
membrane binding site was proposed and electrostatic interactions to negatively charged 
membrane surfaces were suggested as the binding mechanism [27]. Experimental data to 
prove this mechanism are so far only available to a limited extent. When purified M1 was 
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exposed to liposomes and liposomes with bound M1 were separated from unbound M1, pro-
tein association was only detected for negatively charged vesicles. The negatively charged 
vesicles in this artificial system were produced from a mixture of specific lipids, namely 
phosphatidylcholine, cholesterol, and negatively charged phophatidylserine [27,84]. However, 
interactions with other lipids are not reported. Membrane suspensions derived from lysed 
cells were also tested. Here a M1 association was visualized [27]. Since cellular membranes 
consist of more than three different lipids, the role of the huge lipid spectrum needs to be fur-
ther specified. It is possible that phosphatidylserine is not the only M1 target. 
 
Figure 4 3D structure of the N-terminal part of M1. (A) Superimposed ribbon cartoon of the crystal structures at 
pH 4 (gold) and pH 7 (blue). The major secondary structure elements are nine α-helices linked by loop regions. 
β-sheets are not visible. Adapted from [68]. (B) Electrochemical surface potential of the protein from two differ-
ent views. The protein exhibits enrichment of negative charges (red) and a prominent positively charged (blue) 
patch including the PBS (95–KAVKLYRKLKR–105) which is located on H6. Modified from [83] 
When M1 was expressed in mammalian epithelial cells it was found in the nucleus and at-
tached to membranes [56]. The plasma membrane, the membranes of Golgi apparatus and ER 
as well as transport and storage vesicles were targeted by M1. Studies performed with fluo-
rescent proteins showed a spotted distribution of M1 [58]. Experiments with fluorescent ER 
and Golgi markers revealed a co-localization of M1 with the Golgi apparatus [85]. Why M1 
was found in association with the Golgi is matter of ongoing research. 
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1.2 Lipid membranes 
Lipid membranes play a crucial role in both the structure and the function of all – prokaryotic 
and eukaryotic – cells. They define the cellular space in total (plasma membrane) as well as in 
eukaryotic cells internal organelles (mitochondria and plastids) and compartments (nuclear 
membrane, smooth and rough endoplasmic reticulum, Golgi apparatus, endosomes, and ly-
sosomes). 
They display a uniform overall structure, basically a six nanometer thick double layer of lipid 
molecules with embedded (integral) and peripheral proteins. Membranes function as barriers 
which enable regulated transport of molecules from outside inwards and vice versa by protein 
activity. In addition, many cellular enzymes are attached to membranes where they are con-
centrated on a lateral plane and facilitate efficient interactions [86]. A continuous exchange of 
vesicles maintains transport of cargo which is not directly transported via the cytoskeleton or 
diffusion through the cytoplasm. Beside this, membranes serve as an assembly site for cellular 
proteins, like clathrin coated pits, or for virus particles. 
1.2.1 Cellular lipids 
Mammalian cells contain more than thousand different lipid species [87]. Lipids fulfill three 
general functions: (i) energy storage, (ii) matrix of cellular membranes, (iii) first and second 
messengers in signal transductions and molecular recognition processes.  
Glycerophospholipids are the major lipid component in the membrane. These lipids are com-
posed of three components: (i) the headgroup molecule which is attached via a phosphoester 
bond to (ii) glycerol. Two fatty acid chains (iii) can be found at the other originally hydroxy-
lated C-atoms of the glycerol, also attached via ester bonds. Major glycerophospholipids 
found in the cell are phosphatidic acids (PA), phosphatidylcholines (PC), phosphatidyletha-
nolamines (PE), phosphatidylserines (PS), and phosphatidylinsitols (PI) with one to three ad-
ditional phosphorylations [88]. 
The second abundant group of molecules is the group of sphingolipids. These molecules show 
a trimodular composition similar to glycerophospholipids. The skeletal structure component is 
sphingosine. The amino group of this molecule functions as attachment site for fatty acids, the 
resulting molecule is classified as ceramide. Substituents can be bound to the primary hy-
droxyl group of sphingosine through esterification. The most prominent sphingolipid sphin-
gomyelin is depicted in Figure 5. Glycoglycerolipids and glycosphingolipids are glycosylated 
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forms of membrane lipids [86]. The carbohydrate moiety of the headgroup can range from a 
single sugar to very complex polymers.  
 
Figure 5 Membrane lipids of epithelial Madin-Darby canine kidney cells. Cholesterol, phosphatidylcholine, and 
phosphatidylethanolamine represent the major components of epithelial cells. Less abundant are PI, PS, SM, 
diacylglycerol, PA, PG, ceramides, and gangliosides like GM3. Adapted from [88]. 
The attached fatty acids differ in chain length and number of double bonds within the chain. 
The degree of unsaturation in the side chains and the concentration of lipids with unsaturated 
side chains influence the membrane fluidity. The more unsaturated side chains are present the 
higher the fluidity of the membrane is. 
Another group of membrane molecules are sterols including cholesterol, the most abundant 
sterol in mammalian cells. These molecules incorporate between phospholipids and sphingo-
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lipids. Hydrogen bonds between the sterols hydroxyl group and the lipid headgroups as well 
as hydrophobic interactions are the driving force for this incorporation. 
Minor components of membranes are free fatty acids, lysophospholipds, mono- and diacyl-
glycerides, as well as polyisoprenoid lipids. 
The lipid composition is dynamic. For epithelial morphogenesis a major shift of the composi-
tion from sphingomyelin to glycosphingolipids, together with an increase in phosphati-
dylethanolamine and cholesterol content could be observed whereas the opposite changes 
took place during an epithelial-to-mesenchymal transition [88]. 
1.2.2 Cellular lipid transport and membrane traffic  
Glycerophospholipids are mainly synthesized at the interface of cytosol and membrane. The 
bacterial phospholipid synthesis is located at the cytosolic site of the plasma membrane, 
whereas eukaryotic cells produce their lipids mainly at the smooth endoplasmic reticulum. 
The synthesized lipids are incorporated into the cytoplasmic site of the membrane. The trans-
location of lipids from one leaflet to the other is accomplished by flip-flop mechanisms. Flip-
flop can occur spontaneously or controlled by membrane proteins called flippases. These pro-
teins bind lipids on one membrane leaflet, transport in an energy-dependent step and release 
the bound lipid at the other leaflet (reviewed in [89]). Action of P-type ATPases like yeast 
Dnf1p and Dnf2p allows the maintenance of the different compositions of inner and outer 
leaflet of the plasma membrane. They keep the content of aminophospholipids like PS and PE 
in the outer leaflet low by specific transport to the inner leaflet where PS is enriched [90]. 
The ER is the major lipid production site in eukaryotic cells. It overlaps with the nuclear 
membrane. The other compartments achieve their supply of lipids by two transport mecha-
nisms. Lipid transfer proteins shuttle specific lipids between membranes whereas vesicles 
allow transport of formed membranes. Transport with lipid carrying proteins involves a con-
tinually growing group of proteins. These proteins act at membrane contacts sites between the 
ER and the Golgi apparatus or the Golgi and the plasma membrane. The ceramide transporter 
CERT was active between ER and Golgi membranes [91]. Nir2 was identified as a PI/PC 
transfer protein, shuttling PC from the Golgi to the ER and phosphatidylinositol back, from 
which phosphatidylinositol-4-phosphate (PI4P) is subsequently synthesized at the Golgi 
membranes [92]. The activity of these proteins enriches specific lipids at the respective com-
partments.  
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The major transport form for lipids is the vesicle. A huge and still growing number of proteins 
are involved in the establishment and trafficking of vesicles in the cell, regulating vesicle 
identity, local lipid synthesis, and vesicle targeting. Clathrin-coated vesicles can be formed 
from the plasma membrane as well as the Golgi apparatus. They mediate endocytic events and 
endosomal vesicular traffic [93,94,95]. COP (coat protein) vesicles of type I are involved in 
bidirectional transport in the Golgi apparatus as well as recycling of proteins from the Golgi 
to the ER [96]. Vesicles organized by COPII emerge from the ER and export secretory pro-
teins towards the Golgi complex [97,98]. 
All these mechanisms taken together enable the cell to sort lipids and proteins specifically to 
distinct sites of the cell. These transport pathways are used by viruses, like influenza, to sort 
their components. For example, influenza hemagglutinin highjacks the secretory pathway on 
its way from the ER through the Golgi to the viral assembly site at the plasma membrane [99]. 
1.2.3 The plasma membrane  
As mentioned before, membranes function as barriers. This function is especially important at 
the outermost membrane, the plasma membrane. Nutrients and liquids are taken up through 
this membrane. Signals are perceived and transmitted inwards. Beside these major functions 
of the regular cellular life cycle other events can be observed here. Assembly and budding of 
the new influenza viral particles occur at the plasma membrane [62]. 
The lipids provide the matrix for incorporated proteins. The plasma membrane exhibits a pro-
nounced difference in the lipid composition of the cytoplasmic and extracellular leaflets. Hu-
man erythrocytes were extensively analyzed as a model system for the plasma membrane. 
Their outer leaflet contains mostly phosphatidylcholine and sphingomyelin while the inner 
leaflet consists mainly of phosphatidylethanolamine and phosphatidylserine. The phosphati-
dylinositolphosphates are also not homogeneously distributed across the plasma membrane. 
Phosphatidic acid, phosphatidylinositol and phosphatidylinositol-4,5-bisphosphate were 
mainly present at the inner leaflet [100]. This assymetric appearance of lipids leads to a nega-
tively charged cytoplasmic lipid leaflet (see Figure 6A). Beside this leaflet dimorphism a lat-
eral heterogeneity of the lipid distribution was found in the plasma membrane. Lipid domains 
called rafts are enriched in cholesterol, sphingomyelin, and glycerophospholipids which carry 
saturated fatty acids, and specific proteins [101,102]. The local enrichment of these specific 
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lipids creates a liquid ordered phase state. These liquid ordered plasma membrane rafts are 
surrounded by lipids in a liquid disordered organization [103]. 
Clustering of proteins was observed in a sterol-dependent manner [104]. The incorporated 
proteins carry specific raft signals, like cysteine palmitoylation close to the transmembrane 
domain [105] or glycosylphosphatidylinositol (GPI) anchors with saturated fatty acids [106]. 
Interestingly, the influenza hemagglutinin was found among those proteins, since it clusters 
cholesterol dependent in mammalian cells [52,53]. There are hints that rafts are also present at 
intra cellular membranes like the ER [107] and they may serve as sorting platforms in the cell. 
Figure 6 summarizes the transversal lipid distribution and presents a model of the lateral or-
ganization of the plasma membrane.  
 
Figure 6 Composition and organization of the plasma membrane. (A) Leaflet composition of the plasma mem-
brane. Adaptad from [100]. SM and PC were shown to reside mostly in the outer leaflet; PS and PE were de-
tected in the inner leaflet. Phosphoinositols and its phosphorylated derivatives were distributed on both leaflets. 
(B) Model of the lateral heterogeneity within the plasma membrane. GPI-anchored proteins, transmembrane raft 
proteins cluster together with glycosphingolipids and cholesterol into rafts. Non-raft proteins are excluded.  
GSL = Glycosphingolipid, GPL = Glycerophospholipid. Modified from [108]. 
1.2.4 Influenza protein mediated plasma membrane modification 
The influenza proteins HA, NA, and M2 belong to the group of integral membrane proteins. 
All three proteins own one α-helical membrane domain which consists mainly of hydrophobic 
amino acids [109,110,111]. A lipid raft association was shown for HA and NA [109,112]. The 
intrinsic equipment that facilitates HA raft association was identified. Mutation of specific 
amino acids in the transmembrane domain of HA revealed the amino acids 
530-WILWISFAI-538 as essential for HA raft association [109]. The transmembrane domain 
and cytoplasmic tail of HA together own three cysteine residues (C551, C559, C562 in HA of 
the H7N1 strain) which are acylated [113]. The raft association of HA was reduced when 
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these cysteines were substituted [53,114]. The raft targeting signals of NA were also assessed 
via mutagenesis of specific amino acids in the transmembrane domain and cytoplasmic tail. 
The mutation of the amino acids 27-GINIISIWIS-35 in NAs transmembrane domain led to 
reduced raft association of NA [110]. Acylation of NA was not reported. From this data it was 
surmised that HA and NA recruit raft lipids to the assembly site of the virus particle (reviewed 
in [51,62,115]). The enrichment of HA and NA in rafts at the budding site is the first step dur-
ing influenza assembly. But the final particle formation can only be accomplished when the 
membrane is curved, a bud is developed, and fission of the elongated bud occurs. Virus-like 
particles (VLPs) were formed, when HA or NA were expressed alone in cells [75,116]. Analy-
sis of HA in model membranes revealed, that full length HA or its transmembrane peptide do 
not bent or tubulate the membrane when they are reconstituted into giant unilamellar vesicles 
(GUVs) [117]. Similar results were obtained when HA was analyzed in giant plasma mem-
brane vesicles that resemble the plasma membrane. Therefore, cellular factors must be in-
volved in the HA based VLP production. Combined expression of HA, NA, M2 and M1 en-
hanced VLP formation significantly [75]. This could have been the result from more efficient 
bud closure and fission of the closed VLPs. An impact of the influenza proton channel M2 in 
fission of virus particles was shown by production of mutant virus particles with altered M2. 
The mutation did not hinder the bud formation, but the release of the formed viruses was 
stopped [111,118]. Bending of membranes independent of other influenza proteins was shown 
when M2 was reconstituted into GUVs. The 17 amino acids long amphipathic helix in the 
cytoplasmic tail of M2 mediated this bending [111]. M2 was not found to be a raft protein, 
even though it carries a palmitoylation in its cytoplasmic tail [115,119]. Co-localization of M2 
with HA was shown [120,121]. An interaction between HA and M2 would link M2 to the 
other viral spike proteins and could induce M2 mediated membrane bending. 
A role for M1 in the orchestration of the budding process has been proposed. Several studies 
showed a direct influence of M1 on the shape of the final virus [80,122]. Single mutations in 
the NLS region of M1 could induce a shift from spherical viruses towards filamentous ones 
[123]. The change of the viral shape needs modification of the viral membrane and 
membrane-bound proteins. M1 was not able to induced VLP formation when it was expressed 
alone in cells. The VLP production was triggered efficiently when HA, NA, M2, and M1 were 
expressed together. The formation of a M1 layer inside of the VLPs could be shown [75]. This 
indicated a connection between these four proteins at the membrane level. An interaction of 
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M1 with the cytoplasmic tails of all three membrane proteins was shown [28,57,58]. 
Interestingly, M1-M2 interactions influence the shape of the budding influenza particle 
[28,120,124]. A current model by Rossman et al. [115] summarizes all the described protein-
membrane and protein-protein interactions (Figure 7). The model considers clustering of HA 
and NA in lipid raft domains as an initial step that slightly bends the membrane at the 
assembly site. This bud initiation is further accomplished by M1 binding to the cytoplasmic 
tails of HA and NA and M1-mediated vRNP-attachment to the spike proteins (Figure 7A). 
The next step in the virus formation is elongation of the bud by polymerization of M1. This 
leads to a perpendicular encapsulation of the vRNPs in relation to the plasma membrane. M2 
is recruited to the periphery of the budding site through interactions with M1 (Figure 7B). The 
amphipathic helix of M2 alters membrane curvature at the neck of the bud when it is inserted 
into the raft boundary. This leads to release of the budding virus (Figure 7C and D). 
 
Figure 7 Model for influenza virus budding at the plasma membrane. (A) Initiation of the virus bud by clustering 
of HA (red) and NA (orange) in lipid raft domains. M1 (purple) binds to the cytoplasmic tails of HA and NA and 
cross-links the vRNPs (yellow) to the spike proteins. (B) Elongation of the bud by polymerization of M1. This 
leads to a perpendicular orientation of the vRNPs to the membrane. M2 (blue) is recruited to the periphery of the 
budding site through interactions with M1 and/or HA. (C) Insertion of the M2 amphipathic helix at the raft phase 
boundary alters membrane curvature at the neck of the bud and leads to release of the budding virus. (D) Over-
view of budding influenza viruses seen on the membrane. The sorting of HA and NA into lipid rafts (yellow), the 
formation of a filamentous virion, and membrane scission caused by M2, are depicted. Taken from [115]. 
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A function of M1 as key organizer in the assembly of influenza virus can be derived from the 
M1 controlled formation of spherical or filamentous virions and its interaction with the three 
viral membrane proteins and the vRNPs. Even though the implications of the M1-HA/NA/M2 
interaction for lateral lipid sorting and membrane shape changes have been analyzed to a great 
extent (reviewed in [51,62,115] it is still elusive how M1s intrinsic membrane binding capa-
bility fits into this model. Therefore it is essential to know what M1 does when it is attached 
to the membrane. GUVs and other artificial liposomes can provide a good starting point for 
examination of M1 membrane association. For instance, the appearance of HA and M2 was 
successfully visualized on this kind of vesicles [111,117]. 
1.2.5 Artificial liposomes as model membrane systems for protein interaction 
Different membrane model systems have been established to approach protein-membrane 
interactions at the molecular level. The simplest are artificial liposomes. Such liposomes can 
be produced in different sizes by various methods.  
Small unilamellar vesicles with a diameter below 100 nm were produced by ultrasonification 
of preformed multilamellar vesicles [125]. They can be used as drug delivery systems [126]. 
Large unilamellar vesicles (LUVs) were produced from multilamellar vesicles by extrusion 
through polycarbon membranes with defined pore sizes from 100 nm up to 400 nm [127,128]. 
Soluble molecules can be encapsulated into the lumen of the LUVs and later released in a 
controlled way [129]. LUVs cannot only harbor molecules; they can also provide a surface for 
attachment. ArfGAP1, a GTPase–activating protein (GAP) for ADP-ribosylation factor 1 
(Arf1), could interact with lipid membranes. The curvature of the LUVs played a significant 
role, since binding of ArfGAP1 was stronger when smaller LUVs with a higher membrane 
curvature were used [130]. The membrane composition was shown to play a significant role 
for protein-membrane interaction beside the membrane curvature. Positively charged proteins 
bound to LUVs with negatively charged lipids through electrostatic interaction. This was 
shown for influenza M1. M1 was mixed with LUVs made of phosphatidylcholine, choles-
terol, and negatively charged phosphatidylserine. This mixture was then adjusted to high den-
sity with a high concentrated sucrose solution. Sucrose solutions of lower concentrations were 
overlaid to form a gradient with the LUV-M1 mix at the bottom. Centrifugation was per-
formed. M1 could be detected in the fractions from the low density region of the gradient 
[84]. It was not detected in the low density fractions when 500 mM NaCl, an inhibitor for 
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electrostatic interactions [131], was added to the initial LUV-M1 mix [27]. Thus, flotation 
with LUVs is a convenient method to analyze the parameters (like certain lipids as binding 
partners) that influence M1’s membrane interaction. 
GUVs are suitable for microscopic methods. They can be produced via induced electro-
swelling from surface-attached preformed membranes [132,133]. These micrometer sized 
vesicles allow direct visualization of protein binding to membranes under the chosen experi-
mental conditions. Suitable dyes for labeling both proteins and membranes are required for 
this purpose. During the last decades a plethora of fluorescent lipid analogues has been devel-
oped for membrane labeling [134]. Usually, they can be added directly to the mixture of the 
desired lipids in low concentrations (less than 1% of the total amount of lipids) and give well 
detectable signals [135]. Two strategies can be applied for protein labeling. The protein could 
be visualized via antibodies which carry a dye [136] or the dye is attached to the protein. A 
short tetracysteine stretch could be genetically engineered to the protein of interest. These 
tetracysteine motif was then specifically labeled by biarsenic dyes [137]. 
Another protein labeling method employs a chemical reaction between a reactive amino acid, 
for example lysine or cysteine, and the dye. A widely-used reaction couple is tetramethylrho-
damine-6-maleimide and a cysteine of the protein [138]. 
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2 Aims of this study 
If M1 is a key organizer in the influenza assembly, it has to fulfill several functions. One of 
them is the binding to membranes. It is still elusive how this happens and whether specific 
lipids play a role in this process. Binding of M1 to liposomal membranes of different lipid 
compositions was investigated to address this question. The flotation assays as well as confo-
cal fluorescence microscopy were chosen as methods for this analysis. Beside the affinity test 
to validate potential lipid specificity, structural information needs to be recorded. Nothing is 
known about the intraprotein dynamics upon membrane binding. CD spectroscopy offers the 
possibility for monitoring molecular rearrangements in presence of membrane material. 
Secondary structure and membrane association of genetically engineered mutants were ana-
lyzed and compared with the wild type M1 to characterize the domain structure of M1 and 
domain specific function. Essentially, two questions can be answered by using such mutants. 
First, deletion mutants may unravel the location of membrane binding site(s) in M1. Second, 
site directed mutations in the PBS permit the elucidation of whether this sequence plays a 
significant role at the molecular level of the membrane interaction of the N-terminal M1 do-
main. Furthermore, it is possible to validate the molecular rearrangements of these mutants in 
comparison to the wild type. It may be possible to locate where molecular interactions take 
place. For instance, when rearrangements could only be detected in a deletion mutant lacking 
the N-terminal part but not in a mutant without the C-terminal part, the C-terminus of M1 
could be identified as putative membrane interaction site of M1.  
It is possible to study membrane association and lateral dynamics of M1 in real time by using 
GUVs of distinct composition as target membranes. Standard and confocal fluorescence mi-
croscopes and respective techniques, e.g. fluorescence recovery after photobleaching provide 
the technical and methodological equipment to monitor a possible self-oligomerization of the 
protein on membranes. Indeed, an M1-M1 interaction was proposed as the driving force for 
enrichment of all viral components at the assembly site in the plasma membrane. 
Deeper insights into M1’s function during the assembly of the influenza particle can be 
achieved when the lipid specificity, the membrane binding site and the lateral organization of 
M1 on the membrane are elucidated. 
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3 Materials and Methods 
3.1 Instruments 
AMINCO-Bowman Series 2 – Luminescence spectrometer (Thermo – Fisher Scientific, 
Schwerte, Germany) 
Biophotometer plus (Eppendorf, Hamburg, Germany) 
CD Spectrometer J-720 (Jasco, Gross-Umstadt, Germany) 
Centrifuge Avanti J-20XP (Rotors JA 25.50 and JLA 10.500) (Beckmann Coulter, Krefeld, 
Germany) 
Confocal microscope IX81 with FluoView-1000 scan head (Olympus, Tokyo, Japan) 
Fluorescence microscope X100 (Olympus, Tokyo, Japan) 
FluoroMax-4 (Horiba Yobin Yvon, Unterhaching, Germany) 
FluoStar Optima (BMG Labtechnologies, Offenburg, Germany) 
FUJIFILM FLA-3000 (Fujifilm, Düsseldorf, Germany) 
Osmometer type 6 (Löser Messtechnik, Berlin, Germany) 
Semi-Dry transfer cell “TransBlot SD” (Bio-Rad, Munich, Germany) 
Thermal Cycler “MyCycler” (Bio-Rad, Munich, Germany) 
Ultracentrifuge Optima L-100K (Rotors 45Ti, 70.1Ti, SW40Ti, SW60) (Beckmann Coulter, 
Krefeld, Germany) 
Ultracentrifuge TL-100 (Beckmann Coulter, Krefeld, Germany) 
UV-Vis Spectrometer Lambda 40 (Perkin Elmer Instruments, Waltham, USA) 
Zetazizer Nano (Malvern, Herrenberg, Germany) 
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3.2 Materials 
3.2.1 Enzymes, antibodies, kits, and other “ready-to-use” tools 
Calf intestine phosphatase, T4 DNA ligase, Restrictionenzymes: DpnI, NdeI, XhoI (Fermen-
tas, St. Leon-Rot, Germany) 
Taq DNA polymerase (supplied with 10x PCR buffer) (Qiagen, Hilden, Germany or Peqlab, 
Erlangen, Germany) 
Phusion™ DNA Polymerase Kit (supplied with 5x HF PCR buffer) (Finnzymes, Espoo, 
Finland) 
QIAprep Spin Miniprep Kit, QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) 
IgG from goat anti M1, IgG from goat anti H3N2 (Virostat, Portland (Ma), USA) 
IgG from donkey anti goat, horseradish peroxidase conjugated (Santa Cruz Biotechnology, 
Heidelberg, Germany) 
ECL™-Kit = Amersham ECL™ Advanced Western Blotting Detection Kit (GE Healthcare 
Life Science, München, Germany) 
Micro BCA Protein Assay Kit (PIERCE, Rockford, USA) 
Apoptest™ -FITC Kit, #A700 (VPS Diagnostics, Hoeven, Netherlands) 
PIP Strips™ (Echelon Biosciences, Salt Lake City , USA) 
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3.2.2 Plasmids and Oligonucleotides 
The plasmid pHH21-vM [139] was kindly provided by the group of PD Dr. Michael Veit 
(Free University, Berlin, Germany). pHH21-vM contains the viral genome fragment for M1 
and M2. pET15b (Novagen – Merck, Darmstadt, Germany) was used as acceptor for all clon-
ing procedures. 
 
 
Figure 8 Map of the plasmid pET15b. The plasmid provides ampicillin resistance. It contains a lac operator for 
IPTG inducible protein expression behind the T7 promoter. The multiple cloning site includes a thrombin restric-
tion site and the coding sequence for an His-tag. Open reading frames of proteins for recombinant expression 
were cloned between the restriction sites of NdeI and XhoI. The serine prior the NdeI restriction site was mu-
tated to cysteine for CM1 labeling with fluorophors. 
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All PCR oligonucleotides listed below are shown in 5’ – 3’ orientation and were ordered from 
Invitrogen (Karlsruhe, Germany) in desalted purity. The final oligonucleotide concentration in 
the PCR mixture was 0.4 µM. 
M1-NdeI-fw1 GGGAATTCCATATGAGTCTTCTAACCGAGGTTG (NdeI) 
M1-XhoI-rev1 CCGCTCGAGTCACTTGAATCGTTGC (XhoI) 
M1-fw GACCACAGAGGTGGCATTTG 
M1-rev TCCCATCCGTTTCTGGTAGG 
NP-fw AAGAGCCCTTGTGCGTACTG 
NP-rev GCTCGTTGTGCTGCTGTTTG 
M1-1-fw GCCGTCAAACTATACGCGGCGTTGGCAGCTGAGATAACATTCTATGG 
M1-1-rev CCATAGAATGTTATCTCAGCTGCCAACGCCGCGTATAGTTTGACGGC 
M1-2-fw CCAAATAACATGGATGCAGCCGTCGCACTATACGCGGCGTTGGCAGC 
M1-2-rev GCTGCCAACGCCGCGTATAGTGCGACGGCTGCATCCATGTTATTTGG 
NM1rev1 CCGCTCGAGTCACTGTCTGTGAGACCGATGC (XhoI) 
CM1-for GGGAATTCCATATGGTGGCTACCACCAATCC (NdeI) 
M1Cy GGTGCCGCGCGGCAGCCATATGTGTCTTCTAACCG 
M1Cy rev CGGTTAGAAGACACATATGGCTGCCGCGCGGCACC 
CM1Cys GGTGCCGCGCGGCTGCCATATGGTGGCTACCACC 
CM1Cys–rev GGTGGTAGCCACCATATGGCAGCCGCGCGGCACC 
T7-promotor TAATACGACTCACTATAGGG 
T7-terminator GCTAGTTATTGCTCAGCGG 
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3.2.3 Bacteria and culture media 
DH5α (E. coli) F-, endA1, recA1, hsdR17 (rk- mk+), supE44, λ-, thi-1, gyrA(Na1), relA1, 
Φ80 lacZ∆M15∆ (lacZY A-argF) 
Rosetta (E. coli) F–, ompT, hsdSB (rB–, mB–), dcm, gal, lacY1, λ (DE3), pLysS (CmR) 
BL 21 (E. coli) F–, ompT, hsdSB (rB–, mB–), dcm, gal, λ(DE3) 
LB + Amp 1 % [w/v] Bacto™ Tryptone; 0,5 % [w/v] Bacto™ Yeast Extract; 0,5 % 
[w/v] NaCl; 50 µg/ml Ampicillin in ddH2O 
LB + Amp + Cm LB + Amp + 50 µg/ml Chloramphenicol 
Agar plates for 
DH5α 
1 % [w/v] Bacto™ Tryptone; 0,5 % [w/v] Bacto™ Yeast Extract; 0,5 % 
[w/v] NaCl; 1,5 %  [w/v] Agar; 50 µg/ml Ampicillin in ddH2O 
Agar plates for 
Rosetta 
1 % [w/v] Bacto™ Tryptone; 0,5 % [w/v] Bacto™ Yeast Extract; 0,5 % 
[w/v] NaCl; 1,5 %  [w/v] Bacto Agar™; 50 µg/ml Ampicillin; 50 µg/ml 
Chloramphenicol in ddH2O 
LB+G 1 % [w/v] Bacto™ Tryptone; 0,5 % [w/v] Bacto™ Yeast Extract; 0,5 % 
[w/v] NaCl; 50 µg/ml Ampicillin;  50 µg/ml Chloramphenicol; 0,4 % [w/v] 
Glucose in ddH2O 
Bacto™ Tryptone, Bacto™ Yeast Extract, and Bacto Agar™ were ordered from BD (Becton, 
Dickinson and Company, Heidelberg, Germany). Ampicillin and Chloramphenicol were pur-
chased from Sigma Aldrich (Taufkirchen, Germany) and Serva (Heidelberg, Germany). So-
dium chloride was of analytical reagent grade. Glycerol for freezing of bacteria was delivered 
by Roth (Karlsruhe, Germany). 
3.2.4 Buffers 
All used chemicals in buffers were purchased in analytical reagent grade. 
3.2.4.1 Buffers for protein purification 
Lyses buffer  50 mM sodium phosphate; 250 mM NaCl; 10 mM EDTA, 20 mM DTT; 
pH 7.0 + 16 µg/ml DNase I; 300 µg/ml lysozyme; 1 mM PMSF was added 
shortly before use 
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Washing buffer 1 mg/ml desoxycholate; 20 mM DTT; 1 mM EDTA, pH 7.0; 0.2 mg/ml ly-
sozyme was added directly before use 
Unfolding buffer 100 mM sodium phosphate; 1 mM EDTA; 6 M guanidine hydrochloride; 
50 mM reduced glutathione; pH 7.0 
Refolding buffer 100 mM sodium phosphate; 1 mM EDTA; 0.5 mM oxidized glutathione; 
pH 7.5 
Binding buffer 10 mM sodium phosphate, 120 potassium chloride, 20 mM imidazole, pH 7 
Elution buffer 10 mM sodium phosphate, 120 mM potassium chloride, 250 - 500 mM imi-
dazole; pH 7.0 
NaP buffer 10 mM sodium phosphate; pH 7.0 
NaPKCl buffer 10 mM sodium phosphate; 120 mM KCl; pH 7.0 
Mops buffer 10 mM MOPS; pH 7.0 (KOH) 
3.2.4.2 Buffers for SDS-PAGE, Coomassie-staining, and silver staining  
4x non-reducing 
sample buffer 
5 % [w/v] SDS; 0.05 % [w/v] bromine phenol blue; 25 % [v/v] glycerol; 
12.5 % [v/v] 1M Tris/HCl buffer pH 6.8 
4x reducing sample 
buffer 
= 4x non-reducing sample buffer + 25 % [v/v] β-mercaptoethanol 
1x running buffer 192 mM glycine; 25 mM Tris; 3.5 mM SDS 
 
Table 1 Composition of stacking and separating gel 
Components for 2 SDS-gels  5 % Stacking gel 12 % Stacking gel 15 % Stacking gel 
ddH2O 1.7 ml 3.3 ml 2.3 ml 
30 % Acrylamide / Bisacryla-
mide (“Rotiphorese Gel 30” 
Roth, Karlsruhe, Germany) 
0.5 ml 4.0 ml 5.0 ml 
0.5 M Tris/HCl; pH 6.8 0.75 ml   
1.5 M Tris/HCl; pH 8.8  2.5 ml 2.5 ml 
10 % SDS [w/v] 30 µl 100 µl 100 µl 
10 % APS 30 µl 100 µl 100 µl 
TEMED 3 µl 4 µl 4 µl 
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Coomassie staining 
solution 
0.25 % [w/v] Coomassie Brilliant Blue R – 250, 45 % [v/v] ethanol, 10 %  
[v/v] acetic acid  
washing solution 40 % [v/v] Ethanol, 7.5 % [v/v] acetic acid or 50 % [v/v] methanol; 10 % 
[v/v] acetic acid  
Fixation solution 30 % [v/v] ethanol, 10 % [v/v] acetic acid  
Cross-linking solu-
tion 
30 % [v/v] ethanol, 0.5 % [v/v] glutaraldehyde, 0.2 % [w/v] sodium thiosul-
fate, 0.5 M sodium acetate  
Silver solution 0.1 % [w/v] silver nitrate, 0.02 % formaldehyde  
Developer 2.5 % [w/v] sodium carbonate, 0.01 % formaldehyde 
Stop solution 0.05 M EDTA 
3.2.4.3 Materials for preparation of large unilamellar vesicles (LUV) 
The lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-
phospho-L-serine (DOPS), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-
dioleoyl-sn-glycero-3-phosphate (DOPA), L-α-phosphatidylinositol-4-phosphate (PI4P), N-
palmitoyl-D-erythro-sphingosylphosphorylcholine (SM), 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (N-NBD-DPPE), 1-oleoyl-2-6-
[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl-sn-glycero-3-phosphocholine (C6-NBD-
PC), 1-oleoyl-2-6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl-sn-glycero-3-phos-
phoserine (C6-NBD-PS), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (LR-DOPE) were from Avanti Polar Lipids (Alabaster (Al), USA). 
Cholesterol (Chol), Dipalmitoyl-L-α-phosphatidylinositol-3-phosphate (PI4P), and Dipalmi-
toyl-L-α-phosphatidylinositol-4-phosphate (PI3P) were from Sigma Aldrich (Taufkirchen, 
Germany). 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG) was ordered from Fluka 
(Buchs, Switzerland). The LUVs were produced in NaP, NaPKCl, NaP with 400 mM KCl or 
Mops buffer. 
3.2.4.4 Flotation assay buffers 
25 % Sucrose buffer 25 % [w/v] Sucrose in NaP or NaPKCl or NaP buffer with 400 mM KCl 
75 % Sucrose buffer 75 % [w/v] Sucrose in NaP or NaPKCl or NaP buffer with 400 mM KCl 
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3.2.4.5 Buffers for PIP™ strips 
TBST or TBS 10 mM Tris, 150 mM NaCl, pH 8.0, 0.1 % [v/v] Tween-20 
TBST+BSA or 
TBS+BSA 
10 mM Tris, 150 mM NaCl, pH 8.0, 3 % [w/v] fatty acid free BSA (Sigma-
Aldrich) - (0.1 % [v/v] Tween-20) in TBST+BSA 
3.2.4.6 Solutions for labeling of proteins 
FM solution 2 mM fluorescein-5-maleimide (Invitrogen) in NaPKCl 
TMR solution 0.5 mM 5/6-carboxy-tetramethylrhodamine ethyl-maleimide (emp Biotech 
GmbH, Berlin, Germany) in DMSO 
3.2.4.7 Materials and buffers for GUV preparation and microscopy 
The lipids DOPC, DOPS, 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), N-NBD-DPPE, C6-
NBD-PC, C6-NBD-PS, Chol, PI4P, and PI3P were from Sigma Aldrich. 1,2-dioleoyl-sn-
glycero-3-phosphoglycerol (DOPG) was ordered from Fluka (Buchs, Switzerland). The 
GUVs were produced in swelling buffer.  
Swelling was carried out either on titanium slides or on indium tin oxide coated glass slides. 
 
Swelling buffer  250 mM sucrose + 15 mM NaN3, adjusted to 280 mosm 
Microscopy buffer  5.8 mM NaH2PO4, 5.8 mM Na2HPO4, 250 mM glucose (300 mosm) 
1x binding buffer  10 mM Hepes, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2 
(part of the APOPTEST™-FITC Kit - VPS Diagnostics, Doeven, NL) 
3.3 Methods 
3.3.1 Cloning of M1 
The M1 open reading frame was amplified in a standard PCR with Phusion DNA polymerase 
from the pHH21vM [139] with the oligonucleotides M1-NdeI-fw1 and M1-XhoI-rev1. These 
oligonucleotides provided the restrictions sites for NdeI and XhoI in 3’ and 5’ overhanging 
sequences. The reaction condition in the 20 µl sample were 30 s at 98 °C initial denaturation, 
30 cycles with 10 s denaturation at 98 °C followed by 45 s at a oligonucleotide melting tem-
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perature (Tm) of 59 °C and 30 s at 72 °C extension, final extension step for 10 min at 72 °C 
and cooling to 4 °C until the sample was removed from the cycler. The fragments were doubly 
digested directly after amplification (5 u NdeI in buffer O for 2 h at 37 °C and after addition 
of 10 u XhoI another 2 h at 37 °C, volume 20 µl). The acceptor vector pET15b was digested 
in parallel and dephosphorylated. Purification of the fragments and vector occurred after gel 
electrophoresis using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). The M1 
fragments were inserted into pET15b using T4 DNA ligase according to the manufacturer’s 
manual. The resulting plasmid was named pET15b-M1. Five µl of the ligation were trans-
fected into 50 µl chemical competent DH5α cells and they were cultivated on ampicillin 
plates. A part from one growing clone was added to a 25 µl Taq polymerase containing colony 
PCR mixture with the oligonucleotides M1-fw and M1-rev for M1 sequence detection and 
amplified (15 min at 95 °C, 25 cycles with 30 s at 95 °C + 45 s at Tm = 50 °C + 1 min at 72 
°C, 10 min at 72 °C and cooling to 4 °C). Bacteria clones that contained the sequences of in-
terest were cultured overnight and plasmids were purified with the QIAprep Spin Miniprep 
Kit (Qiagen, Hilden, Germany) and sent for sequencing (SMB – Services in Molecular Biol-
ogy, Berlin, Germany). All plasmids were sequenced between the T7 promoter and T7 termi-
nator region of pET15b using the T7 promoter + T7 terminator oligonucleotides. For long 
term storage 30 % glycerol [v/v] was mixed into the bacteria culture and frozen at -80 °C. 
3.3.2 Cloning of the mutants M1m, NM1, NM1m, and CM1 
For site-directed mutagenesis of the polybasic sequence (PBS) in M1 a double overlap exten-
sion PCR [140] approach was performed with Phusion polymerase. The principle of this 
method is based on a complementary oligonucleotide couple which carries the mutation 
(M1-1-fw + M1-1-rev, M1-2-fw + M1-2-rev) and two the fragment defining primers 
(M1-NdeI-fw1 + M1-XhoI-rev1). 
The first fragment amplification from pET15-M1 occurred in three parts. A PCR with M1-
NdeI-fw1 together with M1-1-rev amplified the 5’ part of the fragment (Tm = 59 °C). In a par-
allel reaction the 3’ part was amplified with M1-1-fw and M1-XhoI-rev1. The two fragments 
were analyzed electrophoretically, purified, mixed in equal volumes of the purified solution 
and used in a third subsequent PCR reaction containing only M1-NdeI-fw1 + M1-XhoI-rev1. 
The resulting product functioned as matrix for amplification of the second mutagenesis step. 
This time M1-NdeI-fw1 + M1-2-rev and M1-2-fw + M1-XhoI-rev1were used. The final PCR 
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product was digested with NdeI and XhoI as mentioned before, purified and ligated into 
pET15b. The resulting plasmid was named pET15b-M1m, transfected and checked via colony 
PCR with M1-fw and M1-rev (Tm = 50 °C). 
The sequences of the N-terminal deletion mutants NM1 and NM1m with mutated PBS were 
amplified with M1-NdeI-fw1 and NM1rev1 from the plasmids pET15b-M1 for NM1 and 
pET15bM1m for NM1m (Tm = 59 °C) and cloned into pET15b giving the plasmids pET15b-
NM1 and pET15b-NM1m. 
The oligonucleotides for the C-terminal deletion mutant CM1 coded on the final plasmid 
pET15b-CM1 were CM1-for and M1-XhoI-rev1 and used as described above. 
3.3.3 Cloning of an additional cysteine into M1, M1m, NM1, NM1m, and CM1 
For incorporation of an additional cysteine via S2C substitution into the open reading frames 
for M1, M1m, NM1, and NM1m, the oligonucleotides listed below were used in a quick 
change PCR reaction. This method was adapted from a procedure developed by Stratagene 
[141]. The plasmids pET15b-M1, pET15b-M1m, pET15b-NM1, and pET15b-NM1m func-
tioned as matrices. These plasmids were amplified in a single PCR with the complementary 
mutagenesis oligonucleotides M1Cy and M1Cy rev. CM1 has no cysteine in its open reading 
frame. The serine located two amino acids ahead in the N-terminal overhang was therefore 
converted to cysteine in the plasmid pET15b-CM1 with CM1Cys and CM1Cys-rev. The plas-
mids with S→C conversion were named pET15b-M1-Cy, pET15b-M1m-Cy, pET15b-NM1-
Cy, pET15b-NM1m-Cy and pET15b-CM1-Cys. Oligonucleotides, which did not define a 
fragment as it is the case in standard PCR, were the basis for this method. Here they in fact 
function as the origin for undetermined amplification with Phusion polymerase in both direc-
tions (30 s at 98 °C; 16 cycles with 10 s at 98 °C, 15 s at 69 °C and 3 min at 72 °C; 10min at 
72 °C and cooling to 4 °C). To prevent transformation of non-mutagenized plasmids, the 
original methylated plasmid DNA was digested with DpnI (45 min, 37 °C, 1x buffer tango) 
and the remaining plasmids were transformed into DH5α cells. Selected clones were analyzed 
by colony PCR. The purified plasmids were sequenced, and stored at -20 °C  
3.3.4 Expression of M1 and its mutants  
For expression of the cloned proteins the respective plasmids were transformed into chemical 
competent E. coli BL21 or Rosetta cells. Several conditions were tested for the expression 
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optimum. The most efficient expression took place when cells were inoculated in 250 ml up to 
one liter LB+G medium in Erlenmeyer flasks to an optical density (OD600) of 0.1 at 600 nm 
and precultivated until an OD600 of 0.7 ± 0.05 was achieved. Then protein production was 
induced with 0.1 – 1 mM IPTG for 3 h at 37 °C with rotational shaking at 200 rpm. Protein 
production was analyzed by SDS-PAGE of 18 µl bacteria lysates pre- and post-induction. For 
this purpose 1 ml culture was centrifuged (1 min at 10,000 xg) immediately and 3 h after in-
duction. The optical densitiy of the culture was measured parallel to centrifugation. The su-
pernatant was discarded and the pelleted cells were resuspended in ddH2O. The volume of 
water was calculated using the following correlation: volume H2O [µl] = OD600 · 100. The 
samples were frozen to -20 °C before gel separation.  
3.3.5 Purification of M1 and the mutants 
The protein expressing culture was centrifuged (10 min, 10000 rpm with JLA 25.50 rotor in 
the Avanti centrifuge, 4 °C). The pelleted cells were resuspended in lyses buffer (10 ml per 
litre original culture volume) and frozen to -80 °C. After thawing the volume was doubled 
with lyses buffer. Lysozyme and DNase I were added to final concentrations of 0.3 and 0.016 
mg/ml. The suspension was shaken for 1 h on ice. The cells were lysed by ultrasonification. 
Cell debris and inclusion bodies were pelleted through centrifugation (20 min, 20000 rpm 
with JA 10.500 rotor in the Avanti centrifuge, 4 °C). M1, M1m, NM1, and NM1 as well as 
their homologues with additional cysteine were purified from pelleted inclusion bodies. The 
protocol is described in Chapter 3.3.5.1. Soluble CM1 was purified from the supernatant of 
bacterial lysates. Details can be found in Chapter 3.3.5.2. A summary scheme for the cloned 
proteins is presented in the Results section (see Figure 20). 
3.3.5.1 Purification from inclusion bodies 
To purify the proteins from inclusion bodies washing buffer with 0.2 mg/ml lysozyme (16 ml 
per 1 litre original culture volume) was added to the lysed cell pellet. The pellet was disrupted 
by stirring to flakes with a glass rod and centrifuged (20 min, 20,000 rpm with JA 10.500 ro-
tor in the Avanti centrifuge, 4 °C). This procedure was repeated three times with washing 
buffer, thrice with lyses buffer containing 20 mM DTT and one final washing step with water 
to remove DTT. The washed inclusion bodies were dissolved with degassed unfolding buffer 
for 1 h at room temperature. Native protein was refolded by dilution of the solution with re-
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folding buffer to the nine fold volume and incubated overnight at 4 °C. It was further purified 
as described in the next subchapter. 
3.3.5.2 Purification of soluble proteins 
The supernatant after lysate centrifugation (for CM1 purification) or the refolded solution (for 
purification of the other proteins) contained soluble protein. Four ml of this liquid were incu-
bated with 1 ml Ni-NTA-agarose beads (Qiagen, Hilden, Germany) for 1 h at 4 °C. The mix-
ture was placed onto polypropylene columns (Qiagen) with sealed exit. The agarose beads 
were allowed to form a homogeneous matrix. After opening of the outlet unbound protein was 
removed. Agarose with bound protein was washed twice with 4 ml of binding buffer. Elution 
buffer was added and eluted protein was collected in 0.5 ml fractions. Eighteen µl were ana-
lyzed by SDS-PAGE. Protein-rich fractions were pooled to 2.5 ml final volume and buffer 
exchange to NaP, NaPKCl or Mops buffer was performed on NAP™-25 columns (GE Health-
care Life Sciences, Freiburg, Germany) according to the manufacturer’s manual. The protein 
concentration [µM] in the fractions was estimated by absorption measurement at 280 nm 
(A280) using the Lambert-Beer and the extinction coefficients and molecular weights listed in 
Table 2 and equation (1). Extinction coefficients and molecular weight calculations were per-
formed on the ORF of M1 and on the mutants including the N-terminal overhang with the 
His-tag using the ProtParam tool on the ExPASy Proteomics Server [142]. Samples were di-
luted in case the measured A280 exceeded a value of 0.8. 
Table 2: Extinction coefficients for M1 and the mutants. Extinction coefficient and molecular weight of M1 and 
the mutants including the N-terminal His-tag were calculated using ProtParam. ProtParam can be found on the 
ExPASy Proteomics Server [142]. 
Protein Extinction coefficient [M-1 cm-1] Molecular weight [g/mol] 
M1 / M1-Cy 14502.5 / 14565 30088.6 / 30104.6 
M1m / M1m-Cy 14502.5 / 14565 29690 / 29706 
NM1 / NM1-Cy 13012.5 / 13075 20391.4 / 20407.5 
NM1m / NM1m-Cy 13012.5 / 13075 19992.8 / 20008.9 
CM1 / CM1-Cys 1490 / 1490 11878.5 / 11894.5 
 
DF10
ε
A
c 6
P
280
⋅⋅=  
c = protein concentration in µM 
Pε = extinction coefficient 
DF = dilution factor 
(1) 
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3.3.6 SDS-PAGE  
Polyacrylamide gel electrophoresis (PAGE) in presence of sodium dodecyl sulfate (SDS) was 
performed for size-dependent separation of proteins according to Laemmli [143] in 1x run-
ning buffer. The Mini-PROTEAN 3 system with a PowerPac 1000 (Bio-Rad, Munich, Ger-
many) was used for gel casting and electrophoresis. The sample for separation was mixed 
with 4x reducing sample buffer for reducing conditions or 4x non-reducing sample buffer for 
non-reducing conditions in a ratio of 3:1 to a final volume of 20 – 25 µl, boiled for 5 min at 
95 °C, and centrifuged for 1 min at 10,000 x g. The supernatant was applied to the stacking 
gel using a Hamilton syringe. Electrophoresis ran for 40 min at 200 V. In case that the sample 
contained fluorescently labeled proteins or lipids, the glass plate stack including the gel was 
scanned for fluorescence with the FUJIFILM FLA-3000 (Fujifilm, Düsseldorf, Germany). 
The gels were afterwards removed and stained for protein using direct immersion in 
Coomassie staining solution. To remove background staining in Coomassie stained gels, these 
gels were rinsed in washing solution for at least 2 h. A silver staining procedure was used for 
protein amounts below the resolution of the Coomassie staining. Therefore the gels were first 
rinsed in fixation solution for 30 min, changed to cross-linking solution for another 30 min, 
washed thrice in ddH2O, and stained with silver solution. The gels were washed shortly in 
ddH2O prior to application of developer and incubation until proteins were visible and subse-
quently rinsed in stop solution. For long term storage gels were dried between cellophane 
films using a vacuum Gel Dryer 543 (Bio-Rad, Munich, Germany). 
3.3.7 Preparation of large unilamellar vesicles (LUVs) 
Large unilamellar vesicles were produced according to a published method [127,128]. In 
brief, lipids were mixed in solvent, and the solvent was evaporated under N2 flow or vacuum 
until a dry film developed. NaP, NaPKCl, NaP with 400 mM KCl, or Mops buffer were added 
in the respective volume to reach the aimed concentration of lipids in solution. The suspen-
sion was homogenised by vigorous vortex motion. Five freeze-thaw cycles (-80 to 50 °C) 
followed to form multilamellar vesicles. The suspension was extruded 10 times through poly-
carbonate filters with 100 nm pore size (Millipore, Schwalbach Ts., Germany) under nitrogen 
atmosphere with a pressure between 10 to 30 bar at 50 °C or through a mini extruder (Avanti 
Polar Lipids, Alabaster (Al), USA) at room temperature. Lipid concentration was determined 
indirectly by measuring absorption spectra of the incorporated fluorescent lipids between 400 
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and 600 nm in a 1:10 dilution of the LUV suspension in methanol. The concentration of fluo-
rescent lipids was calculated using the Lambert-Beer law from the absorption of N-NBD-
DPPE at 463 nm and an extinction coefficient of 21000 M-1 cm-1 [144]. Lissamine Rhodamine 
DOPE was measured at 560 nm and ε = 75000 M-1 cm-1 [144] was used for concentration 
calculations. Fluorescent lipids were incorporated either as 1.5, 1, or 0.2 % of the total molar 
amount of lipids. From this ratio the final lipid concentration was derived. 
3.3.8 Cryo- and transmission electron microscopy of purified M1 and LUVs 
M1 (2.8 µM) in 10 mM Mops buffer was diluted 1:5 and 1:20 in Mops buffer. All three sam-
ples were negative stained for analysis by transmission electron microscopy. Negative stain-
ing was performed as follows. Grids (Quantifoil ® R 3/3, Quantifoil µ tools, Jena, Germany) 
were incubated 30 s at 0.3 mbar in the plasma cleaner (Harrick Plasma, Ithaca, USA). The 
RF-Level was set to high. Samples (3.5 µl) were placed on the prepared grids for 45 s. The 
liquid was removed with a filter paper. Staining solution (3.5 µl, 2 % sodium phosphotung-
state in water, pH 7.4) was applied to the grid for 15 s. The staining solution was removed 
with filter paper. Images were acquired with the transmission electron microscope CM 100 - 
100 kV (Koninklijke Philips Electronics, Amsterdam, Netherlands). 
LUVs and LUVs with M1 were analyzed in cryo-electron microscopy. LUVs with 2 mM lipid 
were prepared as described above in Mops buffer. The suspension was diluted 1:1 with Mops 
buffer or M1 solution. Chloroform-washed grids (Quantifoil® R1.2/1.3) were incubated 30 s 
at 0.3 mbar in a plasma cleaner (Harrick Plasma, Ithaca, USA) before sample application. The 
RF-Level was set to high. The grid was fixed to forceps and placed for the semi-automated 
freezing procedure into the Vitrobot (FEI, Hillsboro, USA). Samples (3.5 µl) were placed on 
the prepared grids for approximately 45 s. The remaining liquid was removed by blotting with 
filter paper. The sample was frozen in liquid ethane immediately after blotting and stored in 
liquid nitrogen until image acquisition. Imaging was performed with the Tecnai G2 Spirit 120 
kV (FEI) equipped with a 2k eagle CD (FEI) utilizing a single tilt liquid nitrogen cryo transfer 
holder model 626 (Gatan, Pleasanton, USA) for the transfer of the sample into the beam. 
Electron microscopy was kindly performed by Jörg Bürger in the group of Thorsten Mielke 
(Ultra structure network, Max Planck Institute for Molecular Genetics, Ihnestr. 73, 14195 Ber-
lin, Germany). 
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3.3.9 Flotation assay 
 
Figure 9 Flotation assay. (1) Sucrose gradients with and without LUVs. The left tube contained a gradient where 
NBD fluorescence can be seen in the 30 % sucrose fraction. The right tube did not contain vesicles. (2) The same 
sucrose gradients after centrifugation for 1 h at 240,000 xg. The NBD fluorescence was detected in the low den-
sity 0 % sucrose fraction of the gradient in the left tube. (3) Four samples were obtained after fractionation. 0 % 
= low density fraction, 25 % = fraction from the middle part of the gradient, 30 % = high density fraction from 
the bottom part of the gradient, R = water solubilized precipitates. These samples were size separated in SDS-
PAGE. (4) PhosphoImager scan of the SDS-gel. Fluorescence of the lipid analogue N-NBD-DPPE was detected 
in the bottom line of the gel. Four samples (R, 0, 25, 30 %) of a gradient with LUVs (left side) and four samples 
(30, 25, 0 %, R) from a gradient without LUVs (right side) are shown here. (5) Silver staining of the same SDS-
gel revealed the distribution of protein in the respective fractions. 
The flotation method is based on a protocol developed by Bigay and colleagues [130,145]. In 
summary, purified protein in NaP or NaPKCl was mixed with the respective LUV suspension 
and buffer at room temperature to reach a final protein concentration of 1.5 µM and a final 
lipid concentration of 1 mM in 100 µl. 66.6 µl of 75 % sucrose buffer were added to adjust 
the solution to 30 % final sucrose concentration in the microfuge tube (Beckmann Coulter 
GmbH, Krefeld, Germany). 133 or 266 µl 25 % sucrose buffer were overlaid and 33 µl NaP 
or NaPKCl followed as final 0 % gradient step. The density gradient was centrifuged for 1 h 
at 4 °C in a TL-100 ultracentrifuge (Beckmann) at 240,000 xg. One 38 or 75 µl fraction was 
taken at room temperature from the top of the gradient. Three 38 or 75 µl fractions from the 
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middle part of the gradient followed, and one 165 µl fraction was taken from the bottom. The 
empty tube was washed with 50 µl ddH2O with vigorous vortexing to remove pelleted pre-
cipitates. Aliquots of the fractions were size separated via SDS-PAGE. Gels were analyzed for 
fluorescence of the lipid analogues using the phosphoImager in fluorescence scan mode. The 
gels were silver stained to analyze the protein distribution. 
3.3.10 PIP™ strips 
Analysis of the interaction of M1 and its mutants with PIP™ strips (Echelon) was performed 
following the manufacturers manual. In brief, the PIP™ strip membrane was blocked in 
TBST+BSA or TBS+BSA for 1 h. M1 was diluted in TBST+BSA or TBS+BSA to a final 
concentration of 0.5 µg/ml. Incubation of the PIP™ strip with the protein took place for 2.5 h 
at 4 °C. The protein solution was removed and the membrane was washed three times in 
TBST+BSA or TBS+BSA. IgG from goat anti M1 (Virostat) was diluted 1:1000 in 
TBST+BSA or TBS-BSA and incubated with the membrane overnight at 4 °C. The membrane 
was washed three times in TBST+BSA or TBS+BSA. IgG from donkey anti goat (horseradish 
peroxidase conjugated, Santa Cruz Biotechnology, diluted 1:5000 in TBST or TBS) was 
added and incubated with the membrane for 1 h at room temperature. The membrane was 
washed three times in TBST or TBS. Signal detection was performed with the ECL-Kit (Am-
ersham) according to the manufacturer’s manual. 
3.3.11 Circular dichroism measurements (CD) 
Protein solutions in NaP, NaPKCl or Mops buffer were measured at concentrations between 2 
and 10 µM in a quartz cuvette with 1 or 0.1 mm light path (Hellma, Mühlheim, Germany) in 
the CD spectrometer J-720 (Jasco, Gross-Umstadt, Germany) at 20 °C. Spectra from 5 – 9 
accumulations were obtained between 185 and 260 nm without liposomes and between 205 
and 260 nm with liposomes. The molar ratio between protein and lipids was 5 – 7 µM protein 
to 1.6 mM lipid. 
( )
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Normalization of the spectra was conducted using equation (2) where θ  is the normalized 
ellipticity in kdeg cm2 dmol-1, CDP(+L) the measured value for the protein ± liposomes, and 
CDB(+L) the measured value for buffer ± liposomes. The offset corresponds to the calculated 
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mean value from 258 to 260 nm, d to the light path length (1 mm or 0.1 mm), c is the protein 
concentration in µM, and N the number of amino acids in the protein. An UV spectrum be-
tween 200 and 340 nm was measured directly prior to CD acquisition to calculate the protein 
concentration. The protein concentration was computed according to Iersel et al. [146]. 
3.3.12 Measurement of dynamic light scattering (DLS) 
Samples for DLS measurements were centrifuged 20 min at 36,000 xg. Forty µl were care-
fully pipetted under a constant air flow into the quartz cell (ZEN 2112 produced by Hellma, 
Mühlheim, Germany for Malvern Instruments, Herrenberg, Germany). The cuvette was sealed 
and inserted into the Zetasizer Nano ZS (Malvern), which was equilibrated for 2 min at 20 °C. 
LUV containing samples were measured three times with six 10 s long runs. Scattering pro-
files were fitted to hydrodynamic diameters applying the Size modus of the Zetasizer Soft-
ware 6.01 (Malvern Instruments) taking solvent and temperature into account. 
3.3.13 Fluorescent labeling of M1 and its mutants  
FM solution was diluted in purified solutions of M1, M1m, NM1, NM1m, and CM1 in 
NaPKCl in a molar ratio of 1 FM : 1 protein. Protein concentration was determined as de-
scribed in chapter 3.3.5. The mixture was incubated 30 min at room temperature. Unbound 
FM was removed by buffer exchange on NAP™-25 columns (GE). The amount of bound FM 
was derived from absorption measurements between 200 and 600 nm, calculating the protein 
concentration from the absorption at 280 nm (see 2.5.5) and the FM concentration from the 
absorption at 494 nm and FM494ε  = 83000 M
-1
 cm-1 [144]. For labeling with TMR, proteins in 
120 mM KF, 10 mM sodium phosphate, pH 7 were mixed with TMR solution to reach a ratio 
of protein to TMR of 1:1. The solution was incubated overnight at 4 °C and frozen to -80 °C 
until buffer exchange on NAP™-25 columns. The TMR amount was calculated with TMR548ε  = 
78000 M-1 cm-1. 
3.3.14 Measurement of Förster resonance energy transfer (FRET) 
This method allows the analysis of local interactions between two molecules. Therefore a 
donor (D) fluorophor with an emission spectrum overlapping the excitation spectrum of an 
acceptor (A) fluorophor are used. This distance-dependent method allows estimations of the 
interaction probability of the two fluorophores and of the orientation of the fluorophores to 
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each other when the partners are well characterized (e.g. protein with a defined size on the 
membrane). 
Samples for FRET measurements were prepared by mixing fluorescence donor and acceptor 
molecules in reaction vessels in a certain molar ratio (see Table 3). Incubation for at least 
10 min followed. The mixture was pipetted into quartz glass fluorescence cuvettes (Hellma). 
Measurements were carried out using the AMINCO-Bowman Series 2 – Luminescence spec-
trometer (Thermo – Fisher Scientific, Schwerte, Germany) or the FluoroMax-4 (Horiba Yobin 
Yvon, Unterhaching, Germany). Energy transfer was measured between several different 
fluorescence donor and acceptor pairs (see table 3). For analysis of each FRET pair four 
spectra were recorded. First, a spectrum of the donor fluorophor emission was acquired in the 
wavelength interval [λD1–λD2] in absence of the acceptor. The donor fluorophor was excited at 
its excitation wavelength (λExD). A buffer spectrum was recorded under same condition as 
second spectrum. The second spectrum was used for background correction of the first spec-
trum. Third, a spectrum of the donor fluorophor emission was acquired in the same interval 
[λD1-λD2] in presence of the acceptor to survey FRET events. Finally, a spectrum in the wave-
lengths [λD1–λD2] for unspecific acceptor excitation at the donor excitation wavelength (λExD) 
was recorded in the absence of the donor fluorophor. The fourth spectrum was subtracted 
from the third spectrum for background correction. Fluorescence intensity was recorded in 
1 nm steps for the different spectra. 
Table 3: Donor and acceptor pairs for FRET measurements.  
Fluorescence donor (c) Fluorescence acceptor (c) λExD [λD1–λD2] 
Tryptophan of M1 (1.8 µM) N-NBD-DPPE in LUVs (0.6 µM) 283 nm 300–550 nm 
Tryptophan of Melittin (1.8 µM) N-NBD-DPPE in LUVs (0.6 µM) 283 nm 300–550 nm 
N-NBD-DPPE in LUVs (20 nM) TMR labeled M1 and NM1 (22 nM) 469 nm 500–600 nm 
    
 
Data procession for FRET between N-NDB-DPPE and TMR-M1 or TMR-NM1:  
The fluorescence emission spectra for this FRET pair were recorded and corrected as 
described above (Figure 10 A and B) and processed as difference spectra. Normalization of 
the N-NBD-DPPE emission spectrum without TMR labeled protein was performed by setting 
the recorded fluorescence intensity of the N-NBD-DPPE emission maximum at 533 nm to 1. 
The same procedure was applied to the N-NBD-DPPE emission spectrum which was recorded 
when TMR was present (Figure 10 C and D). The normalized spectrum of N-NBD-DPPE 
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without TMR was then subtracted from the normalized N-NBD-DPPE spectrum in presence 
of TMR yielding a difference spectrum (Figure 10E). 
 
Figure 10 Data processing for N-NDB-DPPE in DOPC-LUVs or DOPC/DOPS-LUVs and TMR-M1. (A,B) 
Background corrected spectra of N-NBD-DPPE in absence (─) and in presence of TMR (─). (C,D) Normalized 
spectra. The intensity of the N-NBD-DPPE fluorescence emission at 533 was set to 1. The other intensity values 
of the spectrum were calculated using this correlation. (E) Difference spectra for the two FRET pairs. The nor-
malized spectrum of N-NBD-DPPE was subtracted from the normalized spectrum of N-NBD-DPPE recorded in 
presence of TMR-M1.  
3.3.15 Preparation of giant unilamellar vesicles (GUVs) 
Giant unilamellar vesicles were prepared for microscopic visualization of protein-membrane 
interactions. Vesicles were produced by applying AC fields to hydrated lipid films on con-
ducting surfaces [132,133,147,148]. 
In detail, 100 nmol lipids were mixed in chloroform in compositions suitable for the after-
wards performed experiments. The liquid was spotted onto two heated (50 – 60 °C) glass 
slides coated with a conductive indium tin oxide (ITO) layer (Präzisions Glas & Optik, Iser-
lohn, Germany) or titanium plates. One of the titanium plates was shaped like a flat trough 
and a second functioned as lid. Removal of solvent traces was achieved by application of 
pressure below 10 mbar for at least 1 h. The ITO slides were assembled into a chamber by 
placing an insulating Teflon spacer between them and sealed with temperature stable plas-
ticine. The rim of the titanium trough was laminated with parafilm at temperatures of 50 to 
60 °C. Lipids in solvent were spotted and dried when titanium plates were used. Sealing of the 
titanium chamber was performed by a short heating pulse to 50 – 60 °C to the parafilm-lined 
plate and by pressing the lid onto it. The lipid films in the sealed chambers were hydrated 
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with swelling buffer and AC field application followed. An AC frequency of 10 Hz was ap-
plied. The voltage was raised stepwise (6 min per set voltage) from 20 mV to 1.1 V for at least 
three hours. Fission of GUV from the surface was induced by lowering the frequency to 4 Hz 
and changing the voltage to 1.3 V for at least half an hour. 
3.3.16 Fluorescence microscopy 
For examination of various samples two different microscopes were used. Standard fluores-
cence microscopy was performed with the inverted X100 fluorescence microscope (Olympus, 
Tokyo, Japan). Size bars were assigned to the images by the Metamorph (Olympus) software. 
Confocal laser scanning fluorescence microscopy was carried out at the inverted IX81 fluo-
rescence microscope (Olympus) equipped with a Fluoview 1000 scanning unit (Olympus) and 
a 60x oil immersion objective with a numerical aperture of 1.35. Beside phase contrast fluo-
rescence images were recorded. NBD and FITC were excited with the 488 nm laser line of an 
Argon ion laser. Fluorescence was detected for NBD and FITC between 500 and 530 nm. 
TMR was excited with a 559 nm laser diode and the emission was recorded between 570 and 
670 nm. Size bars were assigned to the images by the AS Viewer software (Olympus) that was 
calibrated to the camera and microscope setup. 
For microscopic observation of GUVs, the vesicle solution in swelling buffer was diluted 50 
to 100fold in microscopy buffer or in 1x binding buffer. Fifty µl of this dilution were placed 
on a cover slip (Roth). After settling of the GUVs, images were taken in the equatorial plane 
of the vesicle. For visualization of fluorescently labeled protein, the protein of interest was 
diluted in microscopy buffer or 1x binding buffer prior to addition of GUVs. Annexin V-FITC 
from the APOPTEST™-FITC kit (VPS Diagnostics, Doeven, Netherlands) was diluted 
500fold and incubated for 10 min with the GUVs. TMR labeled M1 and NM1 were diluted in 
microscopy or 1x binding buffer to a final concentration of 0.1 µM, respectively. GUVs were 
added and the samples were examined after 30 min. TAMRA labeled α-Synuclein (kindly 
provided by Martin Stöckl [138]) was diluted to a final concentration of 1 µM in 1x binding 
buffer and incubated for 10 min with the GUVs.  
3.3.17 Fluorescence recovery after photobleaching (FRAP) 
The FRAP methodology was developed in the 1970s to estimate lateral diffusion of fluores-
cent molecules and subsequently improved [149,150]). Today it is a well established and 
 MATERIALS AND METHODS 
  39 
widely used method among microscopists. It was already used to study the dynamics of the 
influenza A ribonucleoproteins in cells [151]. Fluorescent molecules in (lipids) and on (e.g. 
M1) GUV membranes were examined microscopically during this study. Two different re-
gions of interest (ROI) were assigned to a settled GUV. For data acquisition the FluoView 
software application scan over time was locked and collection of 400 to 1200 frames in free 
run modus (corresponds to 8 – 20 seconds observation time) was set for NBD-lipid and 
TAMRA labeled α-Synuclein diffusion. For observation of M1-TMR and NM1-TMR 800-
1200 frames in 0.1 seconds intervals were acquired. In one region an additional ROI was as-
signed and bleached after collection of 5 (M1, NM1) or 20 (NBD, α-Synuclein) frames. Fluo-
rescence intensity was monitored with 1 % laser intensity for TMR and TAMRA and 5 – 7 % 
for NBD and fluorescein. The photomultiplier voltage was adjusted to 600 – 800 mV. For 
bleaching the laser intensity was set to 100 % in tornado mode. The fluorescence intensity 
over time profile for bleached and unbleached ROI of at least six GUVs was recorded and 
normalized. Equation (3) was used for the calculation of the mobile fraction (MFP) of fluores-
cent α-Synuclein, Annexin V, and NM1 according to [152]. Fi was the initial fluorescence 
intensity. F0 was the intensity value that was recorded after the bleaching laser pulse. F∞ was 
the fluorescence intensity in the bleached spot at the end of the experiment.  
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The mobile fraction of the fluorescent lipid analogue C6-NDB-PS (MFL) was calculated for 
samples without any protein and with added NM1-TMR or α-Synuclein-TAMRA using equa-
tion (4). The averaged intensity values of the unbleached spot (Fu) and averaged intensity val-
ues of the bleached spot (Fb) were used. The average was calculated from the intensity values 
which were detected within the last second of the measurement.  
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4 Results 
4.1 M1 binding to lipids – a biochemical and biophysical analysis 
Several studies showed membrane binding of M1, either in cellular [26,56,85] or in in vitro 
systems [27,84] (see chapter 1.1.3). This approach is based on recombinant expressed proteins 
and uses a membrane system where parameters like lipid composition and ionic strength can 
be fully controlled. 
4.1.1 Expression and purification of M1 
Recombinant expressed proteins provide a powerful tool to analyze a protein of interest for an 
intrinsic function in a defined system. They can be isolated in high purity and concentration. 
Tag-free M1 was expressed earlier for crystallization [68,82,83] and biochemical studies 
[27,84]. Elster et al. described a method where His-tagged M1 was purified from the soluble 
fraction of Escherichia coli lysate by affinity chromatography  [153]. His-tagged M1 was also 
used during this study. The tag allowed the convenient purification of M1 (Figure 11) and its 
mutants under similar conditions. 
 
Figure 11 SDS-PAGE of aliquots taken throughout the purification of M1 from E. coli cells. Protein was ex-
pressed at 37°C and aliquots were taken immediately and 3 h after induction with IPTG (0’ and 180’). Postlysis 
fractions of disrupted cells showed inclusion bodies in the pelleted debris (P). Only a minor fraction of M1 could 
be found in the supernatant (SN). M1 was therefore purified from inclusion bodies. M1 was found to be soluble 
in water during the washing procedure with washing buffer (W1-4), lysis buffer (L1-3), and water (Wa1-2). The 
aliquots taken from the washing step with water showed a significant amount of protein. The cleaned inclusion 
bodies were disrupted with unfolding buffer. Refolding was triggered upon dilution with refolding buffer yield-
ing refolded M1 (rfM1). The solution was applied to Ni-NTA agarose and affinity chromatography performed. 
Samples were also taken after the refolded solution passed the column prior to elution (pcM1). These samples 
showed lower M1 content. Eluted fractions yielded high purified M1 (E1-2). 
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Expression of the His-tagged wild type M1 protein (see Material and Methods) led repeatedly 
to inclusion bodies. Since inclusion bodies consist mainly of the precipitated denatured re-
combinant protein [154,155], they allow high yield purification of the desired protein. 
Refolded proteins need to be tested for the reconstitution of their secondary structure. An ana-
lytical tool to estimate the secondary structure of proteins is detection of circular dichroism 
[156]. The CD spectra of folded proteins show a distinct curve progression between 185 and 
260 nm depending on the amount of α-helices, β-sheets, or loops in the backbone. A spectrum 
for M1 and the N-terminal mutant NM1 was published by Arzt et al. [82] (see Figure 12B). 
Contents of structure elements were calculated from these spectra using the CDnn software 
[157]. 58 % α-helical protein structure was estimated for M1. A crystal structure of the N-
terminal domain was obtained in parallel. This CD spectrum and the calculated amount of 
amino acids were used as references for the recombinant expressed, purified, and refolded 
protein. Recombinant wild type M1 showed a clearly α-helical behavior (see Figure 12A). 
The obtained CD spectrum was congruent with the spectrum of M1 published by Arzt et al. 
Furthermore, the amount of α-helical structure was calculated with CDnn. Recombinant ex-
pressed M1 showed 48.0 ± 3.1 % (n = 6) α-helical organization. The difference in the calcu-
lated fractions of α-helical structure could have resulted from the additional 20 amino acids in 
the recombinant M1. These 20 amino acids contain the N-terminally attached His-tag. Analy-
sis of this additional peptide with the protein structure prediction software ProteinPredict 
[158] revealed no helical organization (data not shown). 
 
Figure 12 Circular dichroism spectra of purified M1. (A) The spectrum of M1 was obtained for a 7 µM solution 
of recombinant M1 in NaP buffer at 20 °C. It has α-helical character and is consistent with published data. 
(B) Published CD spectra of M1 (○ 1-252 amino acids) and M1 (+ 1-164), both at 0.25 mg/ml. Taken from [82]. 
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4.1.2 M1 bound to DOPS and DOTAP 
Flotation of vesicles in density gradients offers the possibility to separate vesicle-bound pro-
tein from unbound protein [130,145]. Proteins bound to vesicles float up in the gradient, 
whereas unbound protein stays in the high density fraction at the bottom of the gradient. In 
addition, the binding mechanism can be studied with this method. Ruigrok et al. [27] showed 
in a flotation study an electrostatically mediated binding of M1 to negatively charged vesicles. 
Therefore, lipid specificity of M1 was studied based on that to characterize M1s binding affin-
ity to different lipids in more detail. Large unilamellar vesicles (LUVs) were used as model 
membranes. LUVs offer the opportunity to mimic lipid environments in a highly defined way. 
The preparation method used here enabled the choice of well characterized lipids and thereby 
the modulation of the membrane properties. Beside lipid composition, the conditions of the 
suspending medium can be varied over a broad range, including the pH, ionic strength, and by 
choosing specific lipids the fluidity and phase state of the membrane. Depending on the car-
bon filter used during extrusion of the LUVs the curvature of the membrane can be modified 
[127,130]. The vesicles used during this study were extruded through filters with a pore size 
of 100 nm. 
Using DOPS containing LUVs as positive binding control and uncharged DOPC LUVs as 
negative control provided the basis for analyzing binding to other lipids. Purified M1 floated 
without liposomes was taken as a further control. The gradients were prepared, fractionated, 
and analyzed as described in the Method section 3.3.9. Figure 13A shows where LUV-bound 
protein is located in the post centrifugation gradient. 
The samples were analyzed with SDS-PAGE (see Figure 13B). Lipid content of the respective 
fractions was recorded by scanning for fluorescence of the lipid analogue N-NBD-DPPE. N-
NBD-DPPE was added to the lipid mixture to trace LUVs during the experiment. LUVs con-
taining fractions showed a fluorescent signal after scanning in the bottom line of the SDS-gel 
(see Figure 9). Strong fluorescent signals were obtained in the 0 % fractions; weak signals 
were detected in the 25 % fractions, and the 30 % had no significant fluorescence signal. Pro-
tein content was assigned to the respective fractions after silver staining of the same gel. 
A considerable amount of protein precipitated and remained in the test tube (R fractions) after 
fractionation of the gradient. No fluorescence of N-NBD-DPPE was observed in the Phospho-
Imager scan for these samples. 
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Figure 13 Flotation of M1 with different LUVs. (A) Scheme of the sucrose density gradient after centrifugation. 
(B) Results for flotation of M1 with anionic and cationic LUVs as well as LUVs with raft lipids. Vesicles and 
protein were mixed to final concentrations of 1.5 µM M1 and 0.5 mM lipid in the high density part of the gradi-
ent. Gradients were centrifuged and fractionated. Fractions from the low density (0 %), intermediate (25 %), and 
high density part of the gradient were analyzed. Pelleted protein lipid aggregates were removed after fractiona-
tion by washing with ddH2O (R). For each sample two panels are depicted. The upper panel (M1) shows the 
results of the silver staining, where M1 was visible in the respective fractions. The lower panel (NBD) shows the 
PhosphoImager scan for N-NBD-DPPE fluorescence of LUVs. Molar lipid ratios in LUVs were: DOPC/DOPS = 
4:1, DOPC/DSPS = 4:1, DOPC/DOTAP = 4:1, DOPC/Chol/SM = 1:1:1. Controls: M1 only = M1 floated with-
out vesicles; DNaseI + DOPC/DOPS = DNase I floated with DOPC/DOPS-LUVs. Protein and vesicles were 
mixed at room temperature. Centrifugation was performed at 4 °C, Fractionation was done at room temperature. 
Flotation experiments were performed in NaPKCl buffer with the respective amounts of sucrose. All solutions 
were buffered at pH 7. For further details see Materials and Methods chapter 3.3.9. 
M1 could only be detected in the R and the 30 % fraction when it was floated alone. The 25 
and 0 % fraction of the DOPC control showed traces of M1. Based on this result, a second 
control was established to determine whether M1 interacted with DOPC membranes. DNase I 
was tested as non-floating protein. This protein showed similar traces in the 0 and 25 % frac-
tions as M1 when it was floated with DOPC and DOPC/DOPS LUVs (see Figure 13B), even 
though this protein was shown to be soluble [159]. The traces in the 0 and 25 % fraction of 
M1 in the DOPC-LUVs containing gradient and the DNase I traces were the method based 
background. 
Beside DOPC and DOPC/DOPS-LUVs, vesicles containing anionic DSPS, cationic DOTAP, 
as well as both sphingomyelin and cholesterol were tested. DSPS contains two saturated 
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stearyl chains. This lipid was chosen to examine the influence of the acyl chain on membrane 
binding of M1. DOTAP is an artificial lipid. The headgroup of this lipid harbors trimethyl-
ammoniumpropane which is positively charged at neutral pH. LUVs with sphingomyelin and 
cholesterol were produced to mimic raft lipid microdomains of the plasma membrane [108].  
Significant M1 signals appeared only for liposomes with DOPS, DSPS and DOTAP. A signal 
comparable to DOPC was found for LUVs containing sphingomyelin and cholesterol (Figure 
13B, central panel). An influence of the fatty acid chains of the lipids was not observed. 
DOPC/DOPS- and DOPC/DSPS-LUVs showed similar amounts of attached M1. 
To test whether the here used system (see section 3.3.9, in brief: 5 min incubation of M1 with 
LUVs at pH 7, sucrose step gradient, 1 h centrifugation at 240.000 xg) was comparable to the 
method used by Ruigrok et al. [27] (over night incubation of M1 with LUVs at pH 4, linear 
sucrose gradient from 35 % at the bottom to 0 % on the top, 16 h centrifugation at 
192.000 xg), the ionic strength was varied by removal and addition of KCl. The wild type 
protein showed strong binding to DOPC/DOPS-LUVs in NaP buffer (Figure 14 left panel), 
whereas the binding was slightly reduced in NaPKCl buffer (Figure 14 middle panel) and 
reduced to the level of binding to DOPC-LUVs in 400 mM KCl (Figure 14, right panel). 
Ruigrok et al. reported similar results. 
 
Figure 14 Flotation of M1 at low, medium and high salt conditions. LUVs were prepared in the corresponding 
buffers at pH 7. M1 solutions in NaP were adjusted to the respective salt condition by adding KCl. Preparation 
of the LUVs-M1-mixtures, gradient formation, centrifugation, fractionation, and sample analysis were per-
formed as described above. The upper panel (M1) shows the silver stained M1. The lower panel (NBD) depicts 
fluorescence scans of N-NBD-DPPE. M1 was bound to DOPC/DOPS-LUVs under low and medium salt condi-
tions. M1 binding to DOPC/DOPS-LUVS was reduced to the level of DOPC-LUVs in presence of 400 mM KCl. 
LUV composition: DOPC = pure DOPC, DOPC/DOPS = 4:1. Control: M1 alone = M1 floated without vesicles.  
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4.1.3 M1 changed its structure in presence of DOPC/DOPS-LUVs 
Circular dichroism measurements were performed to analyze M1’s structure when it was 
bound to LUVs. M1 (3 µM final concentration) was analyzed in presence of DOPC- and 
DOPC/DOPS-LUVs. Spectra were measured between 200 and 260 nm. Samples were pre-
pared from mixtures of M1 (3 µM final concentration) with LUVs (1.6 mM final lipid con-
centration). No changes in the spectrum could be observed in presence of DOPC-LUVs. A 
narrower spectrum was recorded in presence of DOPC/DOPS-LUVs. This indicated a loss of 
α-helical content (see Figure 15). 
 
Figure 15 CD spectra of M1 and M1 in the presence of DOPC- and DOPC/DOPS-LUVs. M1 was mixed with 
LUVs to final concentrations of 3 µM M1 and 1.6 mM lipid. The samples were incubated for one hour at room 
temperature. Spectra from 200 to 260 nm were measured at 20 °C after 2 min equilibration in the spectrometer. 
The sample with DOPC-LUVs yielded a spectrum that was similar to M1 without LUVs. DOPC/DOPS-LUVs 
induced a change in the spectrum. 
The presumed loss of α-helical structure was evaluated using the CDnn software. An α-helical 
content of 46.1 ± 7.2 % (n = 3) was calculated from the spectra when DOPC-LUVs were pre-
sent in the sample. 33 ± 4.9 % (n = 2) was calculated when DOPC/DOPS-LUVs were added. 
Additional structural information could be derived from the local minima of the spectra at 208 
and 222 nm. The ratio of the molar elipticity values at these wavelengths is an indicator for 
helix to helix orientations in the protein. Ratios ≥ 1 indicate an α-helical coiled coil secondary 
structure where the α-helices are closely packed. Ratios ≤ 1 indicate existence of loop regions 
[160,161]. The shift in the θ222/θ208 ratio from 0.89 ± 0.02 for M1 in buffer or 0.84 ± 0.07 in 
the presence of DOPC-LUVs to 0.98 ± 0.03 in presence of DOPC/DOPS-LUVs indicated no 
major helix rearrangements of helices in M1.  
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4.1.4 M1 bound to phohatidylinositol-4-phosphate (PI4P) 
Another tool to examine lipid specificities are PIP™ strips. Different lipids including 
headgroup and their respective fatty acid chains were immobilized on nitrocellulose [162]. 
After incubation of these membranes with M1 in presence of Tween 20, M1 was immunologi-
cal detected on spots corresponding to immobilized phosphatidic acid (PA), phosphatidy-
linositol-3,4-bisphosphate (PI34PP), phosphatidylinositol-3,5-bisphosphate (PI35PP), phos-
phatidylinositol-3-phosphate (PI3P), and phosphatidylinositol-4-phosphate (PI4P) (Figure 
15A). When Tween 20 was not used in the buffers, M1 was detected at nearly all spotted lip-
ids except lysophosphocholine (LPC), phosphatidylinositol (PI), phosphatidylethanolamine 
(PE), phosphatidylcholine (PC), and sphingosine-1-phosphate (S1P) (Figure 15B). This dif-
ference led to the conclusion that Tween 20 abolished M1 membrane interactions which have 
a low affinity. A different binding mechanism for the Tween 20 sensitive and the Tween 20 
insensitive M1-lipid interaction seems likely. 
 
Figure 16 M1 visualized on the PIP™ strip with (A) and without Tween 20 (B) during membrane incubation. 
The spotted lipids on the membrane were (starting from the upper left): lysophosphatidic acid (LPA), lysophos-
phocholine (LPC), phosphatidylinositol (PI), phosphatidylinositol-3-phosphate (PI3P), phosphatidylinositol-4-
phosphate (PI4P), phosphatidylinositol-5-phosphate (PI5P), phosphatidylethanolamine (PE), phosphatidylcho-
line (PC), sphingosine-1-phosphate (S1P), phosphatidylinositol-3,4-bisphosphate (PI34PP), phosphatidylinosi-
tol-3,5-bisphosphate (PI35PP), phosphatidylinositol-4,5-bisphosphate (PI45PP), phosphatidylinositol-3,4,5-
triphosphate (PI345PPP), phosphatidic acid (PA), phosphatidylserine (PS), blank. When Tween 20 was absent 
during the binding reaction signals for all spotted lipids except LPC, PI, PE, PC, and S1P were detected. (C) 
Flotation assay in NaPKCl buffer with M1 and LUVs containing 5 mol% PI4P, or PI3P, and 20 mol% DOPS. 
Another aspect, which needed to be taken into account, is the organization of the lipids on the 
PIP™ strip. It is not known that the spotted lipids form lipid layers on the strip or not. To test 
whether the weak and strong M1 signals can be reproduced in a system with lipid membranes, 
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LUVs with PI3P and PI4P were produced in NaPKCl buffer. Flotation in NaPKCl buffer of 
M1 with LUVs containing PI3P showed a weak band for the 0 % fraction (Figure 15 C). The 
signal for PI4P was stronger. The binding affinity of M1 to PI4P was not as prominent here as 
on the PIP strip, but M1 still bound much stronger to PI4P than to PI3P. 
Circular dichroism measurements were performed to analyze structure rearrangements in M1 
in presence of LUVs containing PI3P or PI4P. When DOPC/PI3P-LUVs were added to M1, 
no changes in the spectrum between 200 and 260 nm were observed. DOPC/PI4P-LUVs in-
duced significant changes in the spectral properties of M1 (see Figure 17). 
 
Figure 17 CD measurements for M1 with DOPC/PI3P- and DOPC/PI4P-LUVs. M1 (2.8 µM) and LUVs 
(1.6 mM) were mixed, incubated for one hour and measured at 20 °C.  
The CDnn software was used to determine the α-helical content. An α-helical content of 
50.9 ± 2.0 % (n = 2) was calculated when DOPC/PI3P-LUVs were in the sample, and 
53.0 ± 2.0 % (n = 2) α-helical content was determined from the DOPC/PI4P-LUVs containing 
sample. The θ222/θ208 ratio for DOPC/PI3P-LUVs was 1.0 ± 0.1 and for DOPC/PI4P-LUVs 
1.7 ± 0.1. The θ222/θ208 ratio of 1.7 indicated helix to helix rearrangements in M1. The ob-
served changes in the M1 spectrum in presence of DOPC/PI4P-LUVs were different to those 
observed for DOPC/DOPS-LUVs. The calculated α-helical contents shifted to lower values 
for DOPC/DOPS-LUVs (33 ± 4.9 %) whereas higher values were calculated for DOPC/PI4P-
LUVs. And the θ222/θ208 ratios changed in presence of DOPC/DOPS-LUVs to lower values 
(0.98) whereas higher values were observed with DOPC/PI4P-LUVs. These facts indicated a 
different rearrangement processes in M1 for DOPC/DOPS-LUVs and DOPC/PI4P-LUVs. 
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4.1.5 M1s surface exposed tryptophan did not interact with membranes 
The Trp fluorescence of a small 26 amino acids long membrane binding peptide named melit-
tin was studied in detail by other groups [163]. Upon binding to membranes a strong blue 
shift of its Trp emission could be observed. This change was even more prominent in presence 
of anionic lipids which interacted with the charged amino acids of melittin [164]. This peptide 
was chosen as positive control for membrane interactions involving tryptophan. The goal of 
this experiment was to determine whether membrane binding of M1 could be analyzed by 
examining the emission of the single Trp (W45) of M1. The crystal structure of the N-
terminal part of M1 showed a surface location for this particular amino acid residue. There-
fore, membrane interaction was analyzed by studying Trp fluorescence and Förster resonance 
energy transfer (FRET). 
The experimental set up contained beside Trp a second fluorophor, the headgroup labeled 
lipid analog N-NBD-DPPE. This membrane incorporated fluorophor was used as acceptor for 
FRET from Trp. The NBD fluorophor has an absorption peak between 330 to 350 nm and 
could function as a FRET acceptor for Trp [165]. With this setup two different issues were 
addressed. First, a blue shift in the emission of the single Trp of M1 or melittin as control in 
presence of membranes would indicate that the environment of this Trp had become more 
hydrophobic. Second, FRET between the Trp of melittin or M1 and the N-NBD-PE in the 
LUVs would indicate an interaction of melittin or M1 with the membranes. 
Spectra of M1 or melittin with and without LUVs were measured between 300 and 550 nm. 
The spectra were corrected for the background (buffer or buffer with unlabeled LUVs; see 
Materials and Methods Section 3.3.14). Adding DOPC-LUVs (final lipid concentration 
60 µM) to melittin (1.8 µM) in NaPKCl buffer led to the described blue shift [164] of the Trp 
fluorescence emission. Also a stronger displacement of the emission peak was detected for 
DOPC/DOPS-LUVs (see Figure 18A and C). The very prominent blue shift of the Trp fluo-
rescence indicated that melittin interacted strongly with the LUVs. This allowed the conclu-
sion that melittin was indeed a valuable tool for comparison to the possible reactions of M1. 
The behavior of the single Trp residue of M1 was monitored under equal conditions with 
DOPC- and DOPC/DOPS-LUVs. This experiment brought two results. No blue shift in the 
M1 Trp fluorescence was observed; neither with DOPC-LUVs nor with DOPC/DOPS-LUVs 
(see Figure 18B and D). The emission maximum of the M1 Trp did not change its wavelength 
in presence of DOPC- or DOPC/DOPS-LUVs.  
 RESULTS 
  49 
 
Figure 18 Emission spectra of melittin, M1, and N-NBD-DPPE from DOPC- and DOC/DOPS-LUVs. The exci-
tation wavelength was 283 nm. (A) Spectra for melittin, DOPC-LUVs, and melittin with DOPC-LUVs. The 
emission maximum of the Trp residue of melittin was at 360 nm in absence of LUVs and 354 nm in presence of 
DOPC-LUVs. The intensities of these maxima were 5.6 106 counts per second (cps) at 360 nm and 4.5 106 cps at 
354 nm. The NBD emission intensity at 530 nm of DOPC-LUVs alone was 1.0 106 cps. An intensity of 
1.9 106 cps was measured in presence of melittin. (B) Spectra of M1, DOPC-LUVs, and M1 with DOPC-LUVs. 
(C) Spectra for melittin, DOPC/DOPS-LUVs, and melittin with DOPC/DOPS-LUVs. The emission maximum of 
the Trp residue of melittin was at 340 nm in presence of DOPC/DOPS-LUVs. The intensity at 340 nm was 
4.9 106 cps. The NBD emission intensity of DOPC/DOPS-LUVs alone was 1.2 106 cps. An intensity of 3.1 106 
cps was measured in presence of melittin. (D) Spectra of M1, DOPC/DOPS-LUVs, and M1 with DOPC/DOPS-
LUVs. T= 20 °C. LUV composition: DOPC = pure DOPC, DOPC/DOPS = 4:1. The concentration of N-NBD-
DPPE was 1 mol% of the total lipid. 
Furthermore, the emission intensity of the M1 Trp did not change in presence of the FRET 
acceptor N-NBD-DPPE in DOPC- or DOPC/DOPS-LUVs. This indicated that the Trp residue 
of M1 did not interact with membranes even though it was exposed on the surface of M1. The 
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Förster radius between Trp and NBD was shown to be less than 6 nm [165], the thickness of a 
membrane. The diameter of M1 was given in [82] to be approximately 6 nm. Thus, M1 does 
not attach to membranes with the Trp containing region as no blue shift of its Trp fluorescence 
emission and no significant FRET could be measured. 
4.1.6 M1-TMR bound to DOPC/DOPS-LUVs and DOPC/PI4P-LUVs 
The red fluorescent dye tetramethylrhodamine (TMR) was covalently attached to M1 via a 
reaction between a cysteine of M1 and a reactive maleimide group of TMR for FRET meas-
urements between fluorescently labeled liposomes and M1. The serine after the start methion-
ine of M1 was substituted to cysteine to allow higher TMR-labeling efficiencies (see chapter 
4.2 for more details).  
The purpose of this FRET experiment was to show whether the result of flotation and PIP-
strips can be analyzed in a system where the binding could be monitored upon occurrence and 
not indirectly by biochemical methods like flotation. Furthermore, the position of the attached 
TMR was known to be located at the N-terminus of M1 where the S2C substitution was intro-
duced. N-NBD-DPPE was chosen as FRET partner for TMR-M1. N-NBD-DPPE was incor-
porated into DOPC-, DOPC/DOPS-, DOPC/PI3P-, and DOPC/PI4P-LUVs. The concentration 
of the FRET-donor fluorophore N-NBD-DPPE was kept at 20 nM (from LUVs which con-
tained 1 mol% N-NBD-DPPE) in the cuvette. The final lipid concentration was 2 µM. These 
four versions of LUVs were incubated without TMR-M1 for one hour and the emission meas-
ured between 500 and 600 nm at an excitation wavelength of 469 nm. M1 was added in a sub-
sequent measurement to a concentration of 0.1 µM (22.5 nM TMR-M1). The concentration of 
TMR-M1 was derived from the labeling efficiency of 28 %. Spectra were measured to acquire 
the intensity values for N-NBD-DPPE and TMR. The emission maximum (Emax) of 
N-NBD-DPPE was at 530 nm. The Emax of TMR was around 580 nm.  
The intensity of N-NBD-DPPE at 530 nm was reduced in all samples where TMR-M1 was 
added (see Figure 10). The experiments were performed three times with similar intensity 
changes. The exemplary raw data for the FRET pairs TMR-M1 + N-NBD-DPPE in 
DOPC-LUVs and in DOPC/DOPS-LUVs are presented in Figure 10 A (page 37). The spectra 
from LUVs with and without TMR-M1 were normalized to the N-NBD-DPPE intensity 
maximum at 533 nm for better comparison. Difference spectra were calculated by subtraction 
of the N-NBD-DPPE emission spectrum in the absence of TMR from the N-NBD-DPPE 
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spectrum recorded in presence of TMR (see Figure 19). The difference spectra allowed the 
recognition of small changes in the spectral shape, especially around 580 nm. The difference 
spectra revealed spectral changes for samples containing DOPC/DOPS- and DOPC/PI4P-
LUVs. The intensity at 580 nm increased significantly (Figure 19). Only minor changes could 
be observed for DOPC/PI3P-LUVs. 
 
Figure 19 Difference spectra of N-NBD-DPPE from samples containing LUVs with and without TMR-M1. 
LUVs (final concentration of lipids 2 µM) were incubated without and with TMR-M1 (concentration of M1 
0.1 µM, 28 % labeled with TMR) for one hour. Spectra of the respective LUVs and LUVs with TMR-NM1 were 
measured between 500 and 600 nm, after excitation of NBD at 469 nm. The spectra were normalized to the 
emission maximum at 533 nm. Difference spectra were calculated from these normalized spectra by subtraction 
of the N-NBD-DPPE emission spectrum in the absence of TMR from the N-NBD-DPPE spectrum recorded in 
presence of TMR. The difference spectra represent mean values from three different measurements. The compo-
sition of the LUVs was: DOPC = pure DOPC, DOPC/DOPS = 4:1, DOPC/PI3P = 19:1, DOPC/PI4P = 19:1. N-
NBD-DPPE was added to the lipids at a final concentration of 1 mol % of total lipids. The measurements were 
performed at 20 °C. 
It was possible to reproduce the results from the flotation and PIP-strip experiments for the 
affinity of M1 towards DOPS and PI4P. A specific interaction of M1 with these lipids was 
clearly visible by the increase of the TMR emission around 580 nm resulting from FRET. This 
could be observed for DOPC/DOPS- and DOPC/PI4P-LUVs.  
The change in the NBD emission at 533 nm (Figure 10 A and B) resulted from another 
mechanism. It indicated an interaction of the two fluorophores NBD and TMR which could 
not be due to specific M1 membrane binding. This could be concluded from the fact that the 
NBD emission of all the differently composed LUVs showed a similar spectral change in 
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presence of TMR-M1. The strong spectral change of the NBD emission in presence of TMR-
M1 was an unexpected result and TMR-M1 possibly could have influenced the quantum yield 
of the NBD emission with its presence. Flotation experiments, PIP-strips, and CD measure-
ments suggested that only DOPS and PI4P containing LUVs should have been the target for 
M1 in this kind of experiment. DOPC and PI3P were ruled out as major binding partners in 
the three experiments mentioned above. 
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4.2 Fluorescent labeling of M1 needed protein modification 
The amino acid sequence of M1 includes three cysteines and according to three published 
crystal structures none of these cysteines was coupled into a cystine [81,82,83]. A MALDI-
TOF mass spectrometry study revealed a cystine bridge between C148 and C151 of M1 [166]. 
Several attempts were undertaken to attach cysteine-reactive fluorophores covalently to puri-
fied recombinant M1. The labeling efficiency was determined by absorption measurements. 
The highest labeling ratio for labeled M1 was 3 % of total protein. This was not suitable for 
FRET measurement or fluorescence microscopy. 
An additional cysteine (S2C) was introduced at the N-terminal part of M1, M1m, NM1, and 
NM1m by site directed mutagenesis to enable a more efficient labeling. The sequence of CM1 
did not harbor a cysteine. Serines for substitution were located within the peptide. Therefore, 
a mutation might have induced different folding or reaction behavior. The N-terminal His-tag 
could be used to introduce a cysteine for labeling without altering the CM1 core sequence. A 
serine in the linker sequence to the His-tag two amino acids prior the CM1 start methionine 
(see Figure 8) was substituted.  
All proteins with S→C mutation were purified from inclusion bodies. After analysis of the 
proteins in SDS-gels under non-reducing conditions, additional bands at higher molecular 
weights were observed in distinct distances. This was not visible for the unmodified proteins. 
Deduced from the distance intervals, dimerization of the recombinant protein based on cystine 
formation was hypothesized. Size separation under reducing conditions proved this hypothe-
sis, since no other bands beside the monomeric proteins were recognized (see Supplemen-
tary Figure 2). CD measurements in NaP buffer yielded spectra which were congruent to the 
spectra of the earlier described proteins without additional cysteine. This led to the conclusion 
that the modified proteins were comparable to the unmodified ones, even though they formed 
dimers and trimers. All five proteins could be labeled with significantly increased efficiency. 
After measurements of protein absorption and absorption of the fluorophores TMR or FM and 
calculation of the concentrations, the labeling efficiency was determined to be 17 % for FM 
labeled protein and 20 – 30 % of the proteins carried TMR. All labeled protein samples were 
analyzed in SDS-PAGE for free fluorophor and only a small amount was detected 
(Supplementary Figure 2). The labeled proteins were used in FRET measurements and 
predominantly for microscopy (see chapters 4.1.6, 4.3.4 and 4.4.2 to 4.4.4).  
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4.3 Membrane binding of M1 mutants 
The identification of membrane binding domains or motifs of M1 was another aim of this 
study. Different mutants were expressed beside the wild type matrix protein and purified to 
enable the localization of membrane binding domains within M1. A full length mutant with 
substituted PBS (M1m), a truncated N-terminal fragment (NM1), the N-terminal fragment 
with substituted PBS (NM1m), and a C-terminal deletion mutant (CM1) were produced 
(Figure 20). The PBS was mutated to analyze the role of this particular motif in membrane 
binding. This sequence includes M1’s NLS (101 – RKLKR – 105) and two additional basic 
amino acids that were shown to expose a positively charged patch on the surface of M1 [82]. 
This was proposed to be the interface for electrostatic interactions with negatively charged 
surfaces [27,84]. The flotation assay and CD measurement were used for mutant analysis. 
 
Figure 20 Mutants of M1. M1m contains a modified PBS sequence, with the basic amino acids being exchanged 
to alanines according to [83,153]. NM1 and CM1 reflect the 252 amino acid wild type protein cut in two pieces 
at amino acid 164. NM1m is the N-terminal part of M1 with substituted PBS.  
4.3.1 Expression and purification of M1 mutants 
All mutants containing the N-terminal part of M1 were purified from inclusion bodies. The 
only peptide that was not purified from inclusion bodies was CM1. All proteins yielded final 
concentrations of up to 20 µM after removal of imidazole on NAP™-25 columns. SDS-PAGE 
and Coomassie staining showed a purity of at least 95 % (see Supplementary Figure 1). CD 
spectra indicated mainly α-helical secondary structure for all proteins. The C-terminal part 
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was of heterogeneous secondary structure with low α-helical content according to the spec-
trum obtained from this polypeptide (see Figure 21).  
 
Figure 21 CD spectra of M1 and the purified mutants. Proteins were diluted in NaP buffer to a final concentra-
tion of 7 µM. CD spectra of the purified proteins were measured between 185 and 260 nm. The spectra were 
corrected for buffer background and normalized to molar elipticity θ. The spectrum of M1 was included for di-
rect comparison to the mutants. The spectra were measured at T = 20 °C.  
The fractions of the different structural components can be estimated based on computational 
algorithms. Applying the CDnn software [157] to the spectra of M1m, NM1 and CM1 re-
sulted for M1m in 48.0 ± 3.1 % (131 ± 8 amino acids from 272), for NM1 in 56.4 ± 4.2 % 
(104 ± 8 amino acids from 184) and for CM1 in 22.3 ± 3.0 % (24 ± 3 from 108 amino acids) 
α-helical structured residues. The software predicted a low probability for β-sheets. Prediction 
with PredictProtein provided the evidence for an unfolded state of the additional N-terminal 
20 residues which included the His-tag. Therefore, these 20 amino acids could be excluded as 
part of the α-helical elements. When this was taken into account, the percentage of α-helical 
structured residues changed to 51.8 ± 3.4 % (131 ± 8 amino acids from 252) for M1, 63.3 ± 
4.8 % (104 ± 8 amino acids from 164) for NM1, and 27.4 ± 3.7 % (24 ± 3 from 88 amino ac-
ids) for CM1. Direct comparison with published data revealed only minor differences. The 
CDnn program gave a value of 58 % α-helix for M1 and 68 % for NM1 [82]. When meas-
urement deviations (1.6 – 7.2 %, see Table 4) and given calculation accuracy (± 5 % average 
error) of the CDnn software [157] were taken into account, the acquired values were in the 
range of the α-helix contents that were previously reported [82]. 
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An influence of the deletion on the secondary structure of the mutants could also be analyzed 
by utilizing the CDnn data. The α-helical organized amino acids of NM1 and CM1 (128 
amino acids) and the α-helical content of full length M1 (131 amino acids) were not signifi-
cantly different. This was used as indicator for the structural integrity of the mutants. 
4.3.2 Flotation of the mutant proteins 
The mutant proteins were tested for their membrane binding behavior using flotation experi-
ments (see Figure 22). The LUVs contained the lipids DOPE, DOPC, and DOPS. DOPE was 
used because its headgroup represented another lipid that was found on the inner leaflet of the 
plasma membrane. 
 
Figure 22 Flotation results for the M1 mutant proteins. Equal amounts of protein were floated with DOPC-, 
DOPC/DOPE-, DOPC/DOPE/DOPS- and Raft-LUVs. The gradient samples were analyzed electrophoretically 
and silver stained. The bottom panel shows NBD-fluorescence. Composition of LUVs: DOPC = pure DOPC, 
DOPC/DOPE = 9:1, DOPC/DOPE/DOPC = 7:1:2, Raft = SM/Chol/DOPC = 1:1:1. N-NBD-DPPE was added to 
the lipids at a final concentration of 1 mol % of total lipids.  
M1m showed a binding pattern similar to the wild type protein (compare to Figure 13). M1m 
bound to DOPC/DOPE/DOPS-LUVs whereas no significant binding could be observed for 
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uncharged DOPC-, DOPC/DOPE-, and Raft-LUVs. Compared to M1 and M1m only a small 
fraction of NM1 bound to anionic DOPC/DOPE/DOPS-LUVs and nearly no binding was de-
tected for uncharged vesicles. For NM1m no significant binding to any vesicle type was ob-
served. CM1 bound to all types of vesicles, but with a significant higher extent to 
DOPC/DOPE/DOPS-LUVs. 
In summary, the PBS played a role in membrane attachment of M1. The M1m mutant showed 
a similar binding pattern to the wild type M1 whereas the NM1 mutant of M1 showed a re-
duced binding capability for DOPC/DOPE/DOPS-LUVs. Since membrane binding was com-
pletely abolished for NM1m, it could be concluded that the PBS was able to link NM1 to 
membranes, although with a low affinity. The binding ability of the C-terminal part strongly 
suggests that this part is important for membrane interactions of M1 and might function as an 
additional membrane binding site. 
4.3.3 CD measurements revealed structural changes upon binding to DOPC/DOPS-LUVs 
CD measurements were undertaken to analyze potential changes in the secondary structure of 
the M1 mutant proteins in presence of lipid membranes. Therefore the proteins (3 – 7 µM 
final concentration) were mixed with buffer or DOPC- and DOPC/DOPS-LUVs (final lipid 
concentration 1.6 mM). CD spectroscopy was performed after one hour incubation. No differ-
ences in the spectra could be observed for proteins in buffer or in presence of DOPC-LUVs. 
For M1m and CM1 different spectra were measured when DOPC/DOPS-LUVs were added. 
The behavior of M1m was similar to the behavior of M1. The spectra were comparable in 
intensity of the signal and in curve progression. The spectra for CM1 in the presence of 
DOPC/DOPS-LUVs were shaped differently. These spectra were narrower. This indicated a 
loss in α-helical secondary structure in M1m and CM1. No significant spectral changes ap-
peared for NM1 and NM1m in presence of DOPC/DOPS-LUVs (see Figure 23). 
Additionally, the elipticity θ222/θ208 ratio was evaluated for the spectra of NM1, NM1m, and 
M1m in buffer and when DOPC- or DOPC/DOPS-LUVs were added. The θ222/θ208 ratios of 
NM1 and NM1m in buffer were 0.96 ± 0.02 and 0.97 ± 0.02. For samples where DOPC-
LUVs were added ratios of 0.99 ± 0.01 and 1.03 ± 0.07 were calculated. These values did not 
differ from the ratios 0.98 ± 0.10 and 1.01 ± 0.10 that were derived from spectra in the pres-
ence of DOPS. These values support the conclusion, that NM1 and NM1m did not change 
their structure in presence of DOPC- or DOPC/DOPS-LUVs. A θ222/θ208 ratio of 0.84 ± 0.09 
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was calculated for M1m in buffer and 0.88 ± 0.04 in presence of DOPC-LUVs. These values 
were similar to the θ222/θ208 ratios of M1 in buffer (0.89 ± 0.02) or in presence of DOPC-
LUVs (0.84 ± 0.07). A ratio of 0.92 ± 0.02 was calculated from the spectra taken in the pres-
ence of DOPC/DOPS-LUVs. This value was also comparable to the value that was obtained 
for M1 in presence of DOPC/DOPS-LUVs (0.98 ± 0.03). This indicated similar but no major 
rearrangements in M1m compared to M1. The θ222/θ208 ratios for CM1 in buffer and in the 
presence of LUVs could not be evaluated. The CD spectra of this protein did not show promi-
nent minima at the appropriate wavelengths.  
 
Figure 23 CD measurements for the M1 mutants. The purified proteins in NaP buffer (3 – 7 µM final concentra-
tion) were incubated with NaP buffer or DOPC-LUVs as well as DOPC/DOPS-LUV in NaP buffer (final lipid 
concentration 1.6 mM) for one hour, pipetted into the cuvette and measured between 200 and 260 nm. (A) and 
(C) depict the spectra that were measured for NM1 and NM1m. (B) shows the spectra for M1m. (D) represents 
the data obtained for CM1. The composition of the LUVs was: DOPC = pure DOPC, DOPC/DOPS = 4:1. 
T = 20 °C. 
The CDnn algorithm was applied to spectra of M1m, NM1, NM1m, and CM1 in presence of 
LUVs to analyze the structural changes in detail. Table 4 contains the calculated values for all 
five proteins. M1 was included for direct comparison. No significant differences in the 
α-helical content could be observed for M1 and M1m or NM1 and NM1m in absence of 
LUVs. This led to the conclusion that M1 and M1m as well as NM1 and NM1m had a similar 
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structure. Crystal structures of NM1 and NM1m were obtained by Arzt et al. [83]. The projec-
tion of the two structures on each other was congruent. When the spectra, the calculated 
α-helical contents, the published spectra from [82], and the published crystal structures from 
[83] were taken into account, it is clear that structure of the proteins used in this study were 
similar to those published previously. 
The α-helical content was also calculated for the mutant proteins in the presence of LUVs. 
The calculated α-helical content of all soluble and LUVs-associated mutant proteins was not 
significantly different. Only M1m and CM1 showed reduced α-helical content in presence of 
DOPC/DOPS-LUVs, as indicated by the spectra. The significant change in the spectra and α-
helical content was limited to proteins that contained the C-terminal part. Derived from this, it 
was concluded that only the C-terminus of M1 showed structural rearrangements. 
Table 4 Results from CDnn for M1, M1m, NM1, NM1m, and CM1 in buffer and in presence of DOPC- and 
DOPC/DOPS-LUVs. The CD Spectra [mdeg] of buffer or LUVs in buffer were subtracted. These corrected spec-
tra were imported into the CDnn software in Milli-Degrees modus. Values for M1 were included for direct com-
parison of the mutants to the wild type protein. 
 α-helical content [%] in presence of 
 Buffer DOPC-LUVs DOPC/DOPS-LUVs 
M1 48.0 ± 3.1 (n = 6) 46.1 ± 7.2 (n = 3) 33.0 ± 4.9 (n =2) 
M1m 49.0 ± 1.6 (n = 4) 48.1 ± 5.3 (n = 2) 38.6 ± 2.5 (n = 2) 
NM1 56.4 ± 4.2 (n = 5) 51.6 ± 4.2 (n = 2) 56.5 ± 1.7 (n = 2) 
NM1m 58.0± 4.2 (n = 3) 56.4 ± 1.6 (n = 2) 54.1 ± 2.0 (n = 2) 
CM1 22.3 ± 3.0 (n = 3) 22.9 ± 2.1 (n = 2) 16.5 (n = 1) 
    
    
 
4.3.4 NM1-TMR bound to DOPC/DOPS- and DOPC/PI4P-LUVs 
FRET experiments between N-NBD-DPPE containing LUVs and TMR-NM1 (with S2C 
modification) were performed. Higher FRET efficiencies compared to TMR-M1 were as-
sumed, because NM1 lacked the C-terminal part. The smaller size of NM1 (1.5 ± 0.3 nm 
[82,83]) should have increased the probability for FRET between NM1-TMR and 
N-NBD-DPPE in the membrane, since the maximal distance between the two fluorophores 
was shorter than for TMR on M1 and NBD. The PBS as membrane binding site of NM1 
should have allowed FRET. 
N-NBD-DPPE containing DOPC-, DOPC/DOPS-, DOPC/PI3P-, and DOPC/PI4P-LUVs were 
incubated without and with TMR-NM1 for one hour. Spectra were measured between 500 and 
600 nm to acquire the intensity values for N-NBD-DPPE and TMR. The spectra were proc-
essed as described in Materials and Methods (see section 3.3.14). 
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Emax of N-NBD-DPPE was at 533 nm and of TMR around 580 nm. The intensity of N-NBD-
DPPE at 533 nm was reduced in all samples where TMR-NM1 was added (data not shown). A 
TMR emission intensity increase around 580 nm could be observed for samples with 
DOPC/DOPS-LUVs, DOPC/PI4P-LUVs and additionally for DOPC/PI3P-LUVs (see Figure 
24). Therefore, a similar interaction mode with DOPS containing LUVs could be concluded 
for M1 and NM1. Furthermore, the interaction was independent of the C-terminal part. The 
less pronounced difference in the spectra of TMR-NM1 with DOPC/PI4P- and DOPC/PI3P-
LUVs compared to the obtained data for TMR-M1 (see Figure 19) might indicate a role of the 
C-terminal part in the binding of M1 to PI4P containing membranes. 
 
Figure 24 Difference spectra of N-NBD-DPPE containing LUVs in the absence and presence of TMR-NM1. 
LUVs (2 µM lipids) were incubated without and with TMR-NM1 (concentration of total NM1 0.1 µM, 21 % 
labeled with TMR) for one hour. Spectra of the respective LUVs and LUVs with TMR-NM1 were measured 
between 500 and 600 nm. The spectra were normalized to the emission at 533 nm to visualize possible differ-
ences and processed to difference spectra. Difference spectra of DOPC-LUVs and DOPC-LUVs with TMR-
NM1, DOPC/DOPS-LUVs ± TMR-NM1, DOPC/PI3P-LUVs ± TMR-NM1 and DOPC/PI4P-LUVs ± TMR-
NM1. The composition of the LUVs was: DOPC = pure DOPC, DOPC/DOPS = 4:1, DOPC/PI3P = 19:1, 
DOPC/PI4P = 19:1. The N-NBD-DPPE content was 1mol% of total lipid. T = 20 °C. 
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4.4 M1 organization on surfaces 
The organization of M1 on membranes was approached so far only via electron microscopy in 
virus particles [20,34,123]. No electron microscopic data for M1 on membranes in a virus free 
system were available. M1 was analyzed during this study with dynamic light scattering to 
evaluate the possible size change that M1 might induce upon formation of M1-LUV-particles. 
Electron microscopy on LUVs in the presence of M1 was performed to reveal how M1 is or-
ganized on the LUV surface. Finally, micrometer sized GUVs were analyzed microscopically 
for bound fluorescent M1 and M1 mutants. The organization of M1 on these surfaces was 
approached by fluorescence recovery after photo bleaching (FRAP) experiments. These ex-
periments were also suitable to analyze the influence of M1 on the lateral lipid diffusion. 
4.4.1 DOPC/DOPS-LUV-M1 particles exhibited a considerably increased diameter 
Size measurements were performed to validate the increase in the LUV diameter when M1 
was bound. Dynamic light scattering was chosen for this purpose. Samples of DOPC- and 
DOPC/DOPS-LUVs were analyzed in the absence and presence of different concentrations of 
M1. The amount of protein was chosen in the following way: LUVs were provided with a 
fixed lipid concentration (80 µM). As membranes consist of two leaflets a maximum of 40 
µM surface exposed lipids were available for interaction with M1. M1 was added to final 
concentrations of 30 nM, 0.3 µM, and 0.6 µM. These ratios were based on the assumption that 
M1 has a diameter of approximately 6 nm [82]. An area with a diameter of 6 nm on the LUV 
surface corresponds approximately to 73 lipids assuming a lipid diameter of 0.7 nm [167]. 
Therefore, a ratio of 600 nmol M1 to 40 µmol lipid (1 M1 to 67 lipids) will lead to maximal 
surface coverage, if all proteins bind. A size change of the LUVs of approximately 12 nm was 
expected under this circumstance. No differences in hydrodynamic diameter were observed 
for DOPC-LUVs with or without M1. When DOPC/DOPS-LUVs were analyzed without M1 
and with the respective M1 concentrations a concentration-dependent change in particle di-
ameter was observed. With increasing M1 concentration a significant larger diameter was 
measured. The expected size change of 12 nm was, however, not found. All DOPC/DOPS-
LUVs had larger diameters in the presence of M1 (see Figure 25), even when the surface 
theoretically could not be completely covered by M1. This would have been the case for sam-
ples where 30 nM and 0.3 µM M1 were used. Two possible explanations could explain these 
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data. First, M1 induced vesicle clustering. Second, oligomers of M1 on the membrane could 
be responsible for the dramatic size change. Figure 25 summarizes the data obtained for the 
hydrodynamic diameter of the LUVs in presence of M1. 
 
Figure 25 Dynamic light scattering measurements for LUVs in absence and presence of M1. DOPC- and 
DOPC/DOPS-LUVs were analyzed in presence of 0.03, 0.3, and 0.6 µM M1 (A) DOPC-LUVs showed no 
changes in diameter size when M1 was present. (B) DOPC/DOPS-LUVs in presence of M1. LUV composition: 
DOPC = pure DOPC, DOPC/DOPS = 4:1. The temperature in the samples was 20 °C. 
Cryo-electron microscopy was performed on DOPC/DOPS-LUVs in absence and presence of 
M1. The samples were prepared at similar protein to lipid ratios that were used in the DLS 
experiments. The vesicles without M1 showed a size distribution of 123 ± 27 nm (Figure 26 
A). The size was measured in the cryo-electron microscopic images. The thickness of the 
membrane was measured as well and the value was 7.1 ± 0.1 nm. The analysis of images 
where M1 was present showed no differences to images taken for samples without M1. M1 
was not visible on the membrane (Figure 26 B). As a control for M1 association 
DOPC/DOGS-LUVs were employed. These LUVs contain a lipid analogue with a Ni-NTA 
equivalent headgroup. The N-terminal His-tag of M1 binds to this molecule with high affinity. 
This could be shown with GUVs (see Figure 27 J). DOPC/DOGS-LUVs also showed no visi-
ble M1 on the surface.  
To check whether M1 alone could be observed, solutions of M1 were analyzed in absence of 
LUVs. For these experiments a negative staining procedure with phosphotungstic acid was 
performed to enhance the contrast for transmission electron microscopic imaging. The con-
centrations of M1 were 2.8, 0.6, and 0.2 µM. The acquired images revealed rod shaped parti-
cles (Figure 26 C and D). The amount of visible particles decreased when lower concentrated 
M1 solutions were analyzed. Thus, it could be concluded that these particles were formed by 
M1 oligomers. 
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Figure 26 Cryo- and transmission electron microscopy of M1 and LUVs. (A) Cryo-electron microscopic images 
of DOPC/DOPS-LUVs in the absence and (B) in presence of M1. (C) Image of M1 oligomers. This image was 
derived from 2.8 µM M1 in Mops buffer. (D) M1 oligomers of a 0.6 µM dilution. LUV composition: DOPC = 
pure DOPC, DOPC/DOPS = 4:1 
4.4.2 M1 clusters on anionic GUVs  
GUVs were used as model membranes for the microscopic analysis of the lateral organization 
of M1 on membranes. GUVs were mixed with FITC-labeled Annexin V, TAMRA-labeled 
α-Synuclein and TMR-labeled M1 with C2S modification, incubated for 30 min and analyzed 
by confocal microscopy. The proteins Annexin V and α-Synuclein were used as controls for 
the presence of anionic lipids in the membrane of GUVs and as reference for membrane bind-
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ing of labeled M1 and NM1. Homogeneous coverage of these two proteins on anionic GUVs 
was shown by Stöckl et al.[138]. No protein binding could be observed on DOPC-GUVs.  
Annexin V and α-Synuclein bound to DOPC/PI3P-, DOPC/PI4P-, DOPC/DOPG-, 
DOPC/DOPA- (data not shown), and DOPC/DOPS-GUVs (Figure 27 K and L). The fluores-
cence of Annexin V and α-Synuclein was homogeneously distributed on the GUVs. GUVs 
that contained only DOPC showed no association of M1 (Figure 27 A). GUVs with the lipid 
analogue DOGS were used as positive binding control for M1 attachment in this system. 
DOGS carried a Ni-NTA headgroup which functioned as a binding site for the His-tag of the 
recombinant M1. A detectable amount of M1 bound to these GUVs. DOPC/DOPS-GUVs 
with a DOPS content of 30 % showed a significant amount of bound M1. DOPS at a concen-
tration of 40 % and 50 % was also tested and showed similar binding of M1 (data not shown). 
DOPC/PI3P- and DOPC/PI4P-GUVs were also tested, but only small M1 clusters were ob-
served on GUVs with PI3P (Figure 27 E) whereas significant amounts of M1 could be de-
tected on DOPC/PI4P-GUVs (Figure 27 F). Small clusters and in rare cases faint homogene-
ous distributed M1 were observed for vesicles with 5 – 10 mol% PI4P. Furthermore, the 
negatively charged lipids DOPG and DOPA were tested in this system. An association of M1 
to GUVs with these lipids was observed (Figure 27 C and D). DOPC/DOPG-GUVs showed 
mostly homogeneous distribution of M1 in addition to M1 clusters. Fluorescence of TMR-
labeled M1 was only detected as patches on the GUVs’ surface. Similar M1 clusters were 
observed for GUVs containing DOPS and DOPA. 
Closer inspection of the morphology of these clusters revealed that the majority appeared as a 
layer of homogeneous thickness within the optical resolution of the used microscope. Flake 
like clusters or sometimes tubulated membranes with bound M1 were only rarely observed. 
M1 was not responsible for the formation of tubular membranes, since vesicles without bound 
M1 also exhibited similar membrane protuberances.  
Binding of TMR-NM1 to DOPC- and DOPC/DOPG-GUVs was not observed (not shown). 
Clusters of TMR-NM1 comparable to those of M1 appeared on the surface of DOPC/DOPA-, 
DOPC/PI4P- (not shown), DOPC/DOGS-, and DOPC/DOPS-GUVs (Figure 27 I, J).  
The data for M1 were consistent with data that were acquired with LUVs. Here, DOPG and 
DOPA could be identified as additional binding partners for M1 and NM1. The clustering of 
M1 and NM1 was a consistent phenomenon for several variants of GUVs. This indicated a 
lateral oligomerization process of M1 and NM1 on the membranes.  
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Figure 27 M1-clustering on anionic membranes. GUVs were prepared by electroswelling and harvested. 
TMR-M1 or TMR-NM1 were diluted to 0.1 µM in microscopy buffer or 1x binding buffer. Five µl GUVs and 
45 µl of buffer with TMR-M1/TMR-NM1 were mixed, incubated for 30 min at 25 °C and analyzed microscopi-
cally. (A) M1 with DOPC-GUVs, (B) M1 with DOPC/DOPS-GUVs, (C) M1 with DOPC/DOPG-GUVs, (D) M1 
with DOPC/DOPA-GUVs, (E) M1 with DOPC/PI3P-GUVs, (F) M1 with DOPC/PI4P-GUVs, (G) unusual M1 
clusters perturbing from DOPC/DOPG-GUVs, (H) unusual M1 clusters within DOPC/DOPA-GUVs (in green: 
C6-NBD-PS in the GUV membrane) (I) NM1 with DOPC/DOPS-GUVs (J) NM1 clusters on a DOPC/DOGS-
GUV. FITC-Annexin V (K) and TAMRA-labeled α-Synuclein (L) were used as reference. The composition of 
the GUVs was: DOPC/DOPS = 7:3, DOPC/DOPG = 7:3, DOPC/DOPA = 7:3, DOPC/PI3P = 9:1, DOPC/PI4P = 
9:1, DOPC/DOGS = 9:1. Calibration bar = 5 µm. T = 24 °C. 
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4.4.3 NM1 clusters consist of a rigid network 
The organization of the NM1 clusters was assessed by FRAP. This method allows the moni-
toring of the organization of molecules on surfaces. It is based on the diffusion of fluorescent 
molecules. When a spot in the fluorescent sample is bleached and the fluorescent molecules 
are able to diffuse, then the fluorescence within the bleached spot recovers. The recovery is 
due to the diffusion of unbleached fluorescent molecules into the formerly bleached spot. 
FITC-labeled Annexin V as well as TAMRA-labeled α-Synuclein were used as controls in 
these FRAP experiments. When FRAP was applied to FITC-labeled Annexin V, a lateral 
movement of Annexin V was observed, since a fluorescence recovery was measured after 
bleaching of FITC-labeled Annexing V. α-Synuclein also showed fluorescence recovery on 
unlabeled vesicles. In addition, NM1-clusters on unlabeled GUVs were analyzed. No recov-
ery of TMR fluorescence could be observed in the bleached spot after bleaching of the TMR-
label on NM1 (see Figure 28) and monitoring of the fluorescence intensity for up to 2 min. 
Based on this and the microscopically recorded clusters of M1, the conclusion can be drawn, 
that M1 formed non-diffusible oligomers on the surface of the GUVs. This indicated an inhi-
bition of lateral movement of the NM1 molecules. 
 
Figure 28 Normalized intensity profiles for the fluorescence recovery after photobleaching of FITC-labeled An-
nexin V (A), TAMRA-labeled α-Synuclein (B) and TMR-labeled NM1 (C). Annexin was diluted 500-fold in 1x 
binding buffer. Synuclein was used at a final concentration of 0.1 µM and NM1 also at 0.1 µM in 1x binding 
buffer or microscopy buffer. Forty-five µl of protein solution were mixed with 5 µl GUVs incubated for at least 
10 min and analyzed. Two regions of interest were assigned. The intensity was recorded before bleaching of one 
region. The intensity was monitored for the indicated time period. Normalization was performed by defining the 
first recorded intensity value before bleaching as 1. Mean values and standard deviation of eight (Annexin V and 
α-Synuclein) and six (NM1) measurements are presented. The composition of GUVs was DOPC/DOPS = 7:3. 
The temperature in the microscopy room was set to 24 °C. 
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This indication was further supported by the calculated values for the mobile fractions (MFP) 
of the proteins. MFP was calculated according to equation (3). The calculated values allowed 
the approximation of the amount of mobile fluorophore. A MFP of 0.82 ± 0.1 (n = 8) was cal-
culated for FITC-Annexin V, 0.87 ± 0.06 (n = 8) for α-Synuclein and 0.02 ± 0.03 (n = 6) for 
TMR-NM1. Thus, at least 82 % of all fluorescent Annexin V and 87 % of the α-Synuclein 
were mobile within the measuring interval. In contrast, the MFP value of NM1-TMR led to 
the conclusion that here only 2 % was freely mobile. In summary, the data prove the intrinsic 
clustering behavior of NM1 on the membrane. 
4.4.4 The NM1 clusters do not influence lateral lipid movement 
The direct interaction of the proteins with the lipids was analyzed by an alternative FRAP 
approach. The working hypothesis here was that protein bound lipids should have diffused 
slower than free lipids. Use of C6-NBD-PS labeled vesicles allowed the surveillance of the 
lipid diffusion behavior in presence of NM1 and α-Synuclein. FRAP was performed on vesi-
cles where no protein was added to estimate the lateral diffusion of the fluorescent lipid ana-
logue C6-NBD-PS. Therefore two different areas of one GUV were selected. One spot was 
bleached, the other was not. The fluorescence intensity was recorded for ten seconds after the 
bleaching pulse of the laser. When FRAP was performed in absence of protein the fluores-
cence intensity in the bleached spot recovered within ten seconds to at least 90 % of the inten-
sity in the unbleached spot (Figure 29 A). FRAP on C6-NBD-PS in the presence of a homoge-
neous distributed α-Synuclein revealed no significant effect of the bound protein on the lateral 
movement of the lipids. The recovery in the bleached spot was also at least 90 % compared to 
the unbleached spot (see Figure 29 D). The fluorescence recovery also reached 90 % when 
NM1-TMR was present (Figure 29 B and E). This indicated a free lateral diffusion of 
C6-NBD-PS in the membranes of the GUVs, when NM1 was present on the surface of the 
GUV. 
An additional FRAP experiment was performed to evaluate the influence of the NM1 clusters 
on C6-NBD-PS in an area of the GUV were NM1 was visible and an area where no NM1 was 
detected. This was done to analyze the behavior of the lipids in the proximity of the protein 
cluster. The recorded intensity profiles of the area with protein cluster (Figure 29 E) showed 
no significant difference in the intensity profile compared to the area without protein cluster 
(Figure 29 B). Therefore, it could be concluded that NM1 had no effect on the lateral move-
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ment of the C6-NBD-PS in the area where a cluster was present. Nevertheless, the recorded 
fluorescent images revealed a lateral enrichment of C6-NBD-PS in areas were NM1 clusters 
were present (Figure 29 C and F). 
The fluorescence intensity time curves were analyzed for the mobile fraction of fluorescent 
lipids (MFL). Intensity values, taken in the last second of the measurement, from bleached 
(Fb) and unbleached spot (Fu) were averaged and used in equation (4) to calculate the mobile 
fraction (Table 5). Fu represents the maximal extent of recovery and could therefore be used 
as parameter for the total mobile fraction of fluorophores.  
MFL can be used to describe the extent of the recovery. Differences in the calculated values 
would indicate different lateral diffusion velocities of the lipids induced by the presence of 
 
Figure 29 FRAP profiles of C6-NBD-PS without protein (A) and in the presence of α-Synuclein (D), an area 
without NM1-cluster (B), and an area with NM1 (E). (C) Green fluorescence of C6-NBD-PS (confocal fluores-
cence microscopy image). (F) Red fluorescence of NM1-TMR (confocal fluorescence microscopy image). 
● = Intensity of the bleached spot, ● = Intensity of the unbleached spot. Asterisks highlight areas were 
C6-NBD-PS was enriched and NM1-clusters were present. C6-NBD-PS was added in 1mol% concentration to the 
lipids prior to lipid film formation and electroswelling of the GUVs. The calibration bar represents 5 µm. The 
composition of GUVs was DOPC/DOPS = 7:3. The temperature in the microscopy room was 24 °C. 
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proteins. As controls, lipid movement was analyzed for samples without proteins and bound 
α-Synuclein. MFL was also calculated for the motion of C6-NBD-PS in an area where a pro-
tein cluster was present as well as without a cluster on the same GUV. MFL showed no sig-
nificant differences for all treatments. The visible enrichment of C6-NBD-PS in an area where 
a NM1-cluster was present had not significant influence on the lateral diffusion behavior of 
this fluorescent lipid analogue. 
Table 5 Summary of the calculated values for the approximation of mobile C6-NBD-PS in presence of NM1 and 
α-Synuclein. 
 MFL 
C6-NBD-PS 0.93 ± 0.04 (n = 8) 
C6-NBD-PS + α-Synuclein 0.95 ± 0.03 (n = 7) 
C6-NBD-PS – NM1-cluster 0.91 ± 0.06 (n = 14) 
C6-NBD-PS + NM1-cluster 0.89 ± 0.09 (n = 11) 
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5 Discussion 
5.1 The lipid binding of M1 
New insights into the membrane binding of the matrix protein M1 of influenza were gained in 
this study. The hypothesis that M1 could use a specific lipid as binding partner was analyzed 
via binding assays to LUVs, GUVs, and spotted lipids. The results from these experiments 
revealed, that M1 was not capable of binding to membranes where no charged headgroups 
were present. A strong binding was observed for binding partners with positively and pre-
dominantly negatively charged headgroups.  
Sha and Luo [81] presented a hypothetical model based on their crystal structure of M1 where 
conformational changes in M1’s N-terminal domain exposed hydrophobic areas of M1 upon 
membrane binding. These exposed areas were considered as the driving force for hydrophobic 
interactions of M1 with membranes. Since M1 did not show a significant binding to DOPC 
vesicles and the secondary structure of M1 did not change in presence of DOPC-LUVs 
(Figure 13 to Figure 15), the hydrophobic interaction with phosphatidylcholine as a 
headgroup and the lipids’ backbone with the fatty acids could be excluded as the major bind-
ing partners for M1. 
The mixture of DOPC, cholesterol, and sphingomyelin was used to mimic lipid rafts. Such 
raft domains are the sites of specific protein attachment and clustering. This was shown for 
GPI-anchored proteins like CD 14 and lyn kinase [52,168,169] and membrane proteins like 
hemagglutinin with a special conformation of their transmembrane domain [53,170]. Little is 
known about proteins that attach to lipid domains without a lipid anchor or a specific trans-
membrane domain. It was shown in several studies that the influenza envelope contained liq-
uid ordered lipid structures that were thought to be derived from lipids rafts [171,172]. There-
fore, these microdomains needed to be tested as potential targets of M1 and the results of the 
flotation experiments indicated no specific targeting and clustering of M1 towards uncharged 
liquid ordered membrane domains consisting of typical raft lipids. Cholesterol and sphingo-
myelin were incapable to attract a significant amount of M1 (Figure 13). Furthermore, the 
saturated acyl chains of DSPS had no visible effect on the membrane binding of M1 com-
pared to DOPS in the flotation assay. The appearance of the liquid ordered domains built of 
cholesterol and sphingomyelin in the influenza envelope is therefore not the result of direct 
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M1-lipid interaction. This finding fits into the current model, which is described in detail in 
the introduction (see chapter 1.2.4), that HA and NA recruit these lipids [115] to the viral 
membrane. 
The finding of positively charged headgroups as binding partner indicated a so far unknown 
binding mechanism for the interaction of M1 with other cellular components. Positively 
charged lipid headgroups do not exist in cellular membranes. Other cellular molecules that 
own a local positive surface charge need to be considered as binding partners of M1. Proteins 
are the most likely candidates for this kind of interaction. 
Representatives of naturally occurring negatively charged headgroups were used during this 
analysis. PS was a prominent binding partner during all experiments. This is consistent with 
published data. Ruigrok and coworkers [27,84] showed binding of M1 to PS containing 
membranes. Other lipids had not been reported for M1 binding yet. The data for M1 interac-
tion with negatively charged lipids, which were collected during this study, revealed for the 
first time several different types of lipid headgroups as additional binding partners. Table 6 
summarizes the negatively charged headgroups where binding of M1 was found.  
Table 6 Summary for all negatively charged lipid headgroups which showed attachment of M1 in the different 
systems. + = binding, – = no binding, n. d. = not determined. 
used system 
Headgroup PIP-strip 
– Tween 20 
PIP-strip 
+ Tween 20 LUVs GUVs 
Phosphatidylserine + – + + 
Phosphatidylinositol-4-phosphate + + + + 
Phosphatidylinositol-3-phosphate + - + + 
Phosphatidylinositol-5-phosphate + - n. d. n. d. 
Phosphatidic acid + + n. d. + 
Lysophosphatidic acid + - n. d. n. d. 
Phosphatidylinositol-3,4-bisphosphate + + n. d. n. d. 
Phosphatidylinositol-3,5-bisphosphate + + n. d. n. d. 
Phosphatidylinositol-4,5-bisphosphate + - n. d. n. d. 
Phosphatidylinositol-3,4,5-triphosphate + - n. d. n. d. 
Phosphatidylglycerol n. d.  n. d. n. d. + 
f 
The binding of M1 to the different negatively charged lipids showed differences depending on 
the system used for investigation. Tween 20 abolished the M1 association to certain lipids on 
the PIP strip. Tween 20, as non ionic detergent, is used as emulsifier and solubilizer in bio-
chemical experiments. The function of such a molecule is to reduce the unspecific binding of 
proteins to target molecules [173,174]. PS was among those lipids whose binding by M1 was 
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strongly inhibited in presence of Tween 20. A possible conclusion from this binding reduction 
was that the electrostatic interactions between M1 and PS were abolished. Deduced from this, 
all other lipids that showed similar binding reduction comparable to PS might have interacted 
with M1 in the same way. It was proposed earlier that M1 can bind through electrostatic inter-
actions to membrane surfaces. Indeed, this interaction was significantly reduced when the salt 
concentration (Figure 14) or the pH [27] was changed. This interaction mechanism can now 
be proposed also for the other Tween 20-sensitive lipid interactions of M1 (see Table 6). 
M1 binding was only observed for PI4P, PI34PP, PI35PP, and PA in presence of Tween 20 
(Figure 16). This indicated a different interaction process of M1 towards these lipids. This 
assumption was further supported by the differences in CD spectra obtained with either 
DOPC/DOPS- or DOPC/PI4P-LUVs. The spectra change depended on the LUV composition 
in significantly different ways. Less α-helical organized M1 was present with DOPC/DOPS-
LUVs compared to DOPC-LUVs whereas more α-helices and helix to helix rearrangements 
occurred in presence of DOPC/PI4P-LUVs (compare Figure 15 and Figure 17). The PI4P 
triggered conformational changes in M1 might have led to the detergent resistant binding to 
PI4P. Whether this binding mechanism is sensitive to salt needs verification. 
Based on the results of the flotation experiments, the interaction of M1 with PIP-strips, and 
the by CD obtained structural information, it can be assumed that M1 binds PI4P in a specific 
way. This specific interaction goes beyond the electrostatic interaction, proposed earlier by 
Baudin et al. [84] and Arzt et al. [83], to the other negatively charged lipids tested.  
The current model for the recruitment of M1 to the assembly site of the viral particle can be 
fine-tuned derived from the obtained data. PI4P might facilitate the association of M1 to the 
Golgi apparatus, since PI4P is locally enriched at the lipid membranes of the Golgi apparatus 
(see [175,176] and chapter 1.2.2 for details). M1 interacts there with the cytoplasmic tails of 
HA, NA, and M2. The transport pathway of HA and NA through the Golgi was shown before 
as well as the interaction of M1 with the cytoplasmic tails of the three proteins 
[28,58,75,85,112]. Its further transport might then be facilitated by hitchhiking with the spike 
proteins on transport vesicles during their passage through the Golgi apparatus to the plasma 
membrane. The data allow the assumption that a first step in the viral assembly happens at the 
Golgi membrane. Analysis of fluorescent proteins in a cellular context can provide further 
knowledge for this issue.  
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5.2 The lipid binding domain of M1 
First attempts to localize the membrane binding domain of M1 were undertaken in the 1980s, 
where hydrophobic interaction of N-terminal M1 peptides were proposed as the driving force 
for association to and incorporation into membranes [177]. Sha and Luo [81] also proposed 
hydrophobic amino acids of the N-terminal part as binding mediators when the first crystal 
structures became available. Shishkov et al. revealed by tritium bombardment studies that N-
and C-terminal parts of M1 are in close proximity to the membrane [178] in viral particles. 
Ruigrok and coworkers [84] performed flotation experiments with deletion mutants where 
either the 164 N-terminal amino acids or the 88 C-terminal amino acid containing C-terminal 
peptide were used. The applied liposomes were made of phosphatidylcholine, phosphatidyl-
serine, and cholesterol. M1 and the truncated N-terminal part (1 – 164) showed similar flota-
tion behavior. Both proteins bound to the vesicles and floated. The C-terminal part (165 – 
252) could not be detected in the upper fraction of the gradient [84].  
5.2.1 The C-terminal domain is a membrane binding domain 
A similar flotation system utilizing two additional M1 mutant proteins was used in this study 
to analyze their membrane binding behavior. The PBS-mutant M1m was only present in sig-
nificant amounts in the upper gradient fraction (0 %) when DOPC/DOPE/DOPS-LUVs were 
applied. This indicated that the mutated amino acids of the PBS had no significant influence 
on the ability of M1 to bind to negatively charged membranes. When NM1 (amino acids 1 to 
164 of M1) was floated with DOPC/DOPE/DOPS-LUVs less NM1 was detected in the upper 
fraction in comparison to M1m. The initial concentration of M1m and NM1 in the high den-
sity fraction (30 %) of the gradient prior centrifugation was the same. Different protein 
amounts in the upper fraction after centrifugation should therefore be the result a reduced af-
finity of NM1 to lipid membranes. The PBS mutant of the N-terminal part NM1m was not 
detected in any upper gradient fraction. The mutation of the PBS also abolished the residual 
membrane binding that was found for NM1. This result is the first direct proof for the func-
tion of the PBS as a membrane anchor. The results for NM1 are consistent with published 
data, where this mutant was capable of binding to PS-containing membranes [84]. There are 
no data available for comparison of the in vitro membrane binding behavior of the PBS mu-
tant M1m. But no difference between the membrane binding of M1 and its PBS mutant was 
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shown in floatation experiments utilizing disrupted mammalian cells [85]. This indicates fur-
ther membrane binding sites in M1.  
The C-terminal mutant, CM1, bound with significant affinity to DOPC/DOPE/DOPS-LUVs. 
CM1 was also detected to a small extent in the upper gradient fractions (0%) of the other 
LUVs tested (Figure 22). The hydrophobic interface in one of the α-helices might explain this 
behavior (Supplementary Figure 3). This interface could be shielded in the full length protein, 
since detectable binding to uncharged vesicle was only observed for CM1. The data reveal 
that the C-terminal part of M1 is also capable of associating with negatively charged mem-
branes. The CD measurements further support an interaction of the C-terminus of M1 with 
negatively charged membranes. Only M1, M1m, and CM1 showed structural changes in pres-
ence of DOPC/DOPS-LUVs in comparison to DOPC-LUVs (Figure 23). Actually, the finding 
that CM1 binds to phoshatidylserine-containing membranes is indicated by its amino acid 
sequence. Ten basic amino acids can be found within the 88 amino acid peptide 
(Supplementary Figure 3). Although the structure of this M1 part is not yet known, it is rea-
sonable that a peptide with a theoretical pI of 9.4 would interact with a PS-containing nega-
tively charged membrane at pH 7. 
The appearance of the C-terminal part of M1 in close proximity to the viral membrane was 
shown by tritium bombardment of viral particles [178,179] and by partial bromelain digestion 
of M1 [166]. The binding of CM1 to DOPC/DOPE/DOPS-LUVs conflicts with the published 
data of Baudin et al. [84]. Baudin and coworkers could not detect their C-terminal M1 mutant 
protein in the upper fractions of their used gradient system. The difference in the experimental 
setup could be the reason because in the presented work a system based on silver staining was 
used which is much more sensitive compared to Coomassie as it was used by Baudin et al. 
Based on these new insights into the membrane binding of mutant M1, it can be concluded 
that the PBS as well as the C-terminal part of M1 enable membrane association (see Figure 
30). This was shown when the PBS mutant M1m was found at the membrane but not the N-
terminal PBS mutant NM1m. In addition, the C-terminal part alone was also capable of bind-
ing to LUVs.  
In summary, these data additionally emphasize the role of the NLS in the reproduction cycle 
of the influenza virus. The essential function of this amino acid sequence was shown before. 
The production of infectious viral particles was significantly reduced when this motif was 
mutated [79,180]. Two functions have been postulated for the NLS. First, the transport of 
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newly synthesized M1 into the nucleus of the infected cell [32,181] and second, the associa-
tion to negatively charged membranes via electrostatic interaction [27,83,84]. A mutation of 
the PBS including the substitution of the NLS would abolish both functions in the N-terminal 
part of M1. This study revealed precisely the membrane binding function of the PBS as it 
clearly showed that NM1m was not able to bind DOPC/DOPS-LUVs. 
 
Figure 30 Model of the M1 interaction with PS containing membranes. The presented protein structure is based 
on data published by Shishkov et al.[179]. The tubes represent the α-helices of M1. The N-terminal part of M1 
(blue) contains the PBS on helix 6. The C-terminal part is shown in green. As darker the color as higher is the 
probability of membrane association of the respective M1 part. 
The role of the C-terminal part needs further analysis since structural changes occur here upon 
membrane association. The calculation of the α-helical content revealed a loss of helical or-
ganized amino acids in the bound state that was not seen when uncharged vesicles were pre-
sent. NMR studies on CM1 could elucidate the helical organization of the peptide and the 
orientation of particular amino acids towards the membrane. The C-terminal part of M1 con-
tains several additional basic amino acids. The structure of this part was not yet crystallized. 
CD measurements [82] and modeling based on tritium bombardment [178,179] revealed that 
this M1 part consists of α-helical and unstructured regions (Supplementary Figure 3). The 
potential of this part of M1 for membrane interaction is not yet fully understood but the re-
ported experiments on negatively charged LUVs prove that the C-terminal part of M1 is in-
volved in membrane binding of M1 (Figure 30). 
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5.2.2 NM1 has a PI4P binding site 
The FRET measurements of NM1 in presence of DOPC/PI4P- and DOPC/PI3P-LUVs 
showed results equivalent to the FRET measurements with M1 (Figure 19 and Figure 24). 
This result indicates a function of NM1 in the recognition and binding of M1 to PI4P. The 
C-terminal part of M1 alone seems to be not essential for efficient binding to PS and PI4P. 
The PBS might drive membrane binding mediated by electrostatic interactions. But when 
only electrostatic interactions play a role, a FRET signal for PI3P- and PI4P-containing vesi-
cles should be detected to similar extents. This was not the case. Clearly, a higher FRET sig-
nal for M1 as well as NM1 in presence of DOPC/PI4P-LUVs was detected (Figure 19 and 
Figure 24). A similar binding behavior could be shown in flotation and PIP strip experiments 
for M1 (Figure 16).  
The physiologic relevance for this interaction can be discussed in close connection to the pub-
lished data, where the N-terminal part of M1 was identified as a membrane binding domain 
[27,84]. The involvement of the PBS in PI4P binding of M1 and NM1 is not clear. However, 
the published data for other PI binding proteins [175,182,183,184] (see chapter 5.2.3) indicate 
an involvement of the polybasic sequence of NM1. Further experiments including the 
N-terminal PBS mutant NM1m could clarify this issue. If the NLS was also responsible for 
the PI4P binding of M1 and particularly NM1, the effects of its mutation will result in a fur-
ther loss of function. Beside the deletion of the nuclear localization and the electrostatic inter-
action site a disruption of the PI4P binding site might also lead to misrouting of M1 in the cell 
and thereby to nonviable viral particles.  
5.2.3 PI binding proteins – a comparison to M1 
We do not know the precise mechanism of the interaction of M1 with PI4P. Therefore it might 
be helpful to look at other proteins. Binding to PI was also shown for other viral matrix pro-
teins. The HIV Gag protein interacts specifically with PI45PP. PI45PP is anchored to the N-
terminal matrix domain of Gag by electrostatic interactions between the PI45PP headgroup to 
a basic surface patch of the matrix domain and the insertion of the 2’-fatty acid chain of 
PI45PP into a hydrophobic groove of the protein [182]. Conformational changes occur in Gag 
upon PI45PP binding. These rearrangements lead to the exposure of the sequestered myristyl 
group [182,185] which incorporates into the plasma membrane of the infected host cell. The 
myristate is a result of posttranslational acylation of Gag [186]. A similar membrane associa-
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tion was proposed for the Gag protein of murine leukemia virus [187]. This so-called myristyl 
switch cannot explain the association of M1 to membranes since M1 is not acylated [166], 
and M1 bound with highest affinity to PI4P in presence of Tween 20. 
Analysis of other cellular PI binding proteins without acylations revealed that two structural 
elements were present in proteins with specific interaction to PI. The PI binding protein Pf1 
contains the poly basic sequence –RRKKREQKK– [188]. A similar patch of positively 
charged amino acids was found with the polybasic sequence 95-KAVKLYRKLKR–105 in 
M1 (basic amino acid residues in bold letters, see Figure 20 and Figure 32). 
A zinc finger motif was published to be the second structural element in Pf1 which is neces-
sary for membrane binding [188]. A similar zinc finger motif was present in the amino acid 
sequence 148-CATCEQIADSQHRSH-162 (amino acids of the zinc finger in bold letter, see 
Figure 32) of M1 [79]. This strongly indicated that these two elements were responsible for 
the PI binding in both proteins. Specificity to PI3P was shown for Pf1. This specificity was 
mediated by the polybasic sequence [188]. Since the polybasic sequences differ between Pf1 
and M1, this could explain the preference of M1 for PI4P. 
Proteins with binding to specific PIs localize in defined intracellular membranes. Early en-
dosome antigen 1 (EEA1) was localized preferentially at early endosomal membranes. The 
early endosomal membranes were found to be enriched in PI3P [189] and specific binding of 
EEA1 to PI3P was shown. The FYVE domain of EEA1 was identified as binding site for PI3P 
[190]. This domain showed a zinc finger motif as a prominent feature [191]. It needs to be 
investigated, whether the zinc finger motif of M1 has a similar function towards PI4P as the 
FYVE domain of EEA1 has towards PI3P. 
EpsinR was specifically recruited to the Golgi by its interaction with PI4P [175]. PI4P was 
shown to be enriched in the Golgi membranes [176]. The ENTH domain of EpsinR mediated 
the specific binding of the protein to PI4P. Mutation of the ENTH domain led to a significant 
reduced PI4P binding [175]. Analysis of the surface electrostatic potential of the ENTH do-
main revealed a local enrichment of positively charged amino acid residues on the protein 
surface. This area was proposed to be the binding pocket for PI4P [175]. Comparison of the 
global structure of the first 164 amino acids of epsinR to the first 164 amino acids of M1 re-
vealed that both proteins share structural similarities (Figure 31). They are composed of 
α-helices which build a compact brick shaped structure. Furthermore, both proteins show sur-
face exposed positively charged areas.  
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Differences can be seen beside these similarities. For instance, the positively charged areas 
differ in composition and size. The proposed PI4P binding site of epsinR consists of densely 
packed basic amino acids that build a binding grove. The polybasic patch of M1 is not only 
less densely packed, but it also forms a convex structure rather than a grove. These differ-
ences can result from the absence of PI4P as binding partner during the crystallization of the 
published M1 part.  
 
Figure 31 Surface structures of epsin1 and M1. (A) Epsin1 with and without phosphatidylinositol-1,4,5-
triphosphate. (B) Surface model of M1. The figure shows the putative structures of epsin1 and M1 in the upper 
panel. The lower panel depicts the surface potential maps of epsin1 and M1. Negatively charged amino acids are 
depicted in red (-10 kT e-1) and positive charges are shown in blue (10 kT e-1). The epsin structures were taken 
from [183]. The structures of M1 were computed from the pdb file 1EA3 of M1 that was published in [82]. 
A two-step process was shown for the binding to PI145PPP of the epsinR homologue epsin1 
[183]. This protein binds to the membrane via electrostatic interactions in the first step. The 
formation of an additional α-helix comprises the second step. This rearrangement leads to the 
specific binding groove for PI145PPP (see Figure 31) and insertion of an amphipathic helix 
into the membrane [184]. The complex inserted into the membrane was visualized by electron 
microscopy [184]. M1 also showed rearrangements in its secondary structure when it bound 
to PI4P containing vesicles. The analysis of the CD measurement revealed a gain of α-
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helically organized amino acids. This finding is similar to the rearrangement in epsin1 upon 
its interaction with PI145PPP containing vesicles, even though it is not known yet which 
amino acids rearrange in M1. First measurements revealed that the Trp (W45, see Figure 32) 
containing region of M1 does not interact with membranes. For this region can be assumed 
that insertion of M1 parts into a lipid membrane do not occur, as it was the case for the epsins. 
This was shown experimentally when FRET was not acquired between M1s Trp and N-NBD-
DPPE in LUVs. Furthermore, the fluorescence emission maximum of M1s Trp was not al-
tered. This indicates that at least this region of the N-terminal M1 part is not attached to or 
inserted into the membrane (see Figure 18). 
Taken together, all these facts allow the hypothesis of a comparable binding mechanism 
between M1 and the an ENTH domain containing epsins. Crystallization of M1 with bound 
PI4P could provide proof for this speculation. The interplay of PI4P with parts of M1 
especially the PBS and the zinc finger motif needs to be analyzed in more detail by usage of 
the M1 mutant proteins NM1m and CM1. It can be hypothesized that the NLS and the zinc 
finger motif of M1 play a significant role during membrane binding to PI4P. 
 
Figure 32 Model of M1’s interaction with PI4P containing membranes. The N-terminal domain of M1 (blue) 
with the PBS (dark blue) and the residues of the zinc finger motif (yellow). H10 forms a linker helix between N-
terminal and C-terminal (green) part of M1. At least the helices H6, H9, and H10 have to rearrange for the for-
mation of the specific binding site for PI4P. The single Trp of M1 (W45, purple) is located at the part of M1 that 
does not interact with the membrane. 
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5.3 The lateral organization of M1 on membranes 
The organization of M1 on the membrane was assessed by cryo-electron microscopy already 
in the early 1980s. It revealed a spot-like distribution of 8 nm particles on artificial vesicles 
[192]. Later on fluorescently labeled M1 was analyzed in the cellular context. These experi-
ments provided information about the inner cellular localization of M1 in the nucleus and 
indicated membranes of ER and Golgi apparatus as targets [58,85]. M1 was not yet analyzed 
by fluorescence microscopy on artificial membranes that mimic the plasma membrane. 
5.3.1 M1 can form viral assembly platforms on membranes 
The use of LUVs provided a tool to measure the size of the membrane attached M1 layer by 
dynamic light scattering (Figure 25). Based on the assumption of homogeneous M1 distribu-
tion a size increase of approximately 12 nm should have been measured for model vesicles 
containing the M1 target phosphatidylserine. The measured values significantly exceeded this 
approximation and indicated the attachment of M1 structures larger than 12 nm or vesicle 
clustering. Cryo-electron microscopy of DOPC/DOPS-LUVs in presence of M1 showed no 
vesicle aggregation (Figure 26 B). But M1 was also not visible. The reason for this invisibility 
of M1 might have been the low contrast of the protein in this method. Staining methods [193], 
especially designed for cryo-electron microscopy, can circumvent this issue. Electron micros-
copy of negative stained purified M1 revealed pearl chain-like M1 oligomers up to 50 nm 
length in the preparation (Figure 26 C and D). Attachment of these oligomers might have in-
duced the increased particle size in the DLS samples.  
Oligomerization of M1 without other viral components has been shown [27,84]. 3D modeling 
based on the crystal structure of the N-terminal part of M1 assumed a sheet formation of the 
oligomers [82] or a structure similar to a compressed corkscrew made from a ribbon of pearl 
chain like organized M1 [68]. Similar oligomers might have been the reason for the size in-
crease of the analyzed DOPC/DOPS-LUVs. 
GUVs were also analyzed for the recruitment of M1. Fluorescently labeled M1 could be de-
tected on the surface of all negatively charged unilamellar liposomes. The attached M1 was 
not homogeneously distributed. It formed clusters with lateral diameters in the micrometer 
range which did not spread over the complete GUV surface. The extension of the clusters was 
limited but not restricted to a particular shape or size. Similar clusters were recorded for fluo-
 DISCUSSION 
  81 
rescently labeled NM1 (Figure 27). These M1 and NM1 clusters were not able to initiate 
membrane tubules. The clusters showed a predominantly flat laterally restricted constitution. 
Clusters with an inbound extension were rarely observed. These extensions did not colocalize 
with fluorescently labeled membrane components (Figure 27H). 
A hypothetical model (see Figure 33) for the organization of the M1 oligomers on the surface 
of the GUVs can be developed based on the reported data on M1 oligomerization and the at-
tachment to negatively charged membranes. It can be assumed that the observed clusters are 
composed of M1 arranged into a helical oligomer. This assumption is based on electron mi-
crographs where such structures were found in preparations of M1 from disrupted virus [27] 
and 3D-modeling of the crystal structure [68]. 
 
Figure 33 Hypothetical organization of the M1 clusters on the surface of GUVs. (A) Cluster of M1 on the sur-
face of a GUV. The subunits of the cluster are not to scale. Single oligomers could not be resolved. (B) Helical 
arrangement of oligomerized M1. The model of the helix is based on the electron micrographs presented in [27]. 
The N-terminal part of M1 is presented in blue and the C-terminal part in green. (C) M1 monomer attached to a 
PS-containing membrane. 
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The inability of M1 alone to induce formation of VLPs from the host membrane has been 
published. No sufficient budding of M1 containing particles was observed when M1 was ex-
pressed alone in the cell in a nontoxic system [69,75]. The interaction with cytoplasmic tails 
of HA, NA, and the M2 protein was necessary for the incorporation of M1 into the VLPs 
[26,28,75]. 
The composition of the NM1 clusters was assessed by FRAP experiments. The results re-
vealed a rigid network of NM1 molecules as a cluster fundament, since there was no fluores-
cence recovery observed in the bleached spot. Such a rigid molecule meshwork can also be 
assumed for the full length protein M1, since the observed clusters had a similar constitution 
on the membranes (Figure 27). 
An hypothesis has been proposed that M1-HA or M1-NA heterodimers are brought together 
by homooligomerization of M1 [51,62,115,194]. The results from the confocal microscopy 
studies on M1 and NM1 give the first experimental data that show that M1 and its N-terminal 
domain are indeed capable of oligomerizing on target membranes. M1 interacts specifically 
with the cytoplasmic tails of the viral membrane proteins HA, NA, M2. A lateral oligomeriza-
tion of M1, as it was shown on the surface of GUVs, could cross-link the spike proteins at a 
specific place on the membrane. The appearance of the resulting membrane-protein particles 
was shown by electron microscopy of viruses and VLPs. A spherical structure was always 
observed when virus-like particles were produced, either with or without M1 [75,76]. The 
oligomerization status of M1 was not assessed. Recently, a highly ordered helical M1 oli-
gomer was shown to be the structural fundament for filamentous influenza particles [20].  
5.3.2 M1s N-terminal domain does not assemble the viral lipids 
The direct interaction of M1 or its proposed N-terminal membrane interaction site with lipids 
was so far not directly analyzed. FRAP was used earlier to reveal the diffusion characteristics 
of the influenza polymerase complex in the cytoplasm [151] and of HA on membranes [52]. 
The presented approach for M1 applied two fluorophores, TMR covalently bound to M1 or 
NM1 and C6-NBD-PS in the membrane. They offered the opportunity to acquire data for the 
membrane-bound M1 (see above) and its influence on the lipids that are in close proximity to 
the protein. The result of the FRAP experiments with the N-terminal domain of M1 indicated 
unrestricted movement of phosphatidylserine underneath of the NM1 clusters. The recovery 
curves for the C6-NBD-PS lipid analogue showed similar progressions for all analyzed sce-
 DISCUSSION 
  83 
narios (Figure 29). C6-NBD-PS moved freely without protein and in presence of α-Synuclein. 
Free C6-NBD-PS movement was also observed in areas where NM1 clusters were detected.  
An uneven distribution of C6-NBD-PS fluorescence was observed in some cases when NM1 
clusters were present (Figure 29C and Supplementary Figure 4). This leads to the assumption 
of a specific C6-NBD-PS accumulation beneath the NM1 clusters. This accumulation had no 
effect on the lateral movement of C6-NBD-PS. Analysis for immobile lipid fractions was per-
formed and revealed no significant differences between C6-NBD-PS free of NM1 clusters and 
C6-NBD-PS with NM1 clusters (Table 5).  
For the case that NM1 did not influence the lateral movement of the underlying lipids it is 
possible to conclude that NM1 is not capable of fixing phosphatidylserine below the cluster. 
Thus, an influence on the other lipids can be excluded. It has to be analyzed in further studies 
whether this concept can be extended to the full length M1. The CD measurements revealed 
structural changes of the C–terminal domain in presence of DOPC/DOPS-LUVs. Although 
the observed clusters of M1 and NM1 were similar in their constitution on the membrane it 
cannot be excluded that full length M1 might influence the lateral movement of phosphatidyl-
serine. 
In summary, the interaction of the N-terminal domain of M1 with phosphatidylserine is flexi-
ble and not contributive to membrane lipid sorting or membrane bending as it was described 
for HA and NA [115,195]. The inability of NM1 to influence the lateral movement of PS and 
the finding that M1 does not interact with raft lipids in flotation experiments is consistent with 
published data concerning the essential proteins HA and NA. These two proteins induced for-
mation of VLPs, M1 alone not [75]. M1 can only work as accumulator and cross-linker of 
these proteins at the assembly site at the plasma membrane. Although M1 can attach to the 
membrane independently it might not be capable of fixing certain lipids or bending the mem-
brane when it is not specifically linked to the membrane by a membrane inserted anchor 
[195]. 
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5.4 Conclusion and outlook 
Research on influenza matrix protein M1 covers a wide area. M1 is found throughout the 
whole cell during the infection with the influenza virus. It is visible in the nucleus and spotted 
in the cytosol where it colocalized with intracellular membranes [58,69,76,195]. M1 was 
found at the plasma membrane when the viral membrane proteins were present or M1 itself 
was equipped with a plasma membrane targeting peptide [26,195] in huge amounts and in 
smaller amounts when it was expressed alone [58,85]. This overall appearance suggests sev-
eral different functions of M1 during the influenza replication cycle. While focusing on M1 
membrane binding alone three aspects for analysis were addressed in this study: 
 
1. The association of M1 to specific lipids was assessed by different methods. The results 
revealed a precise set of negatively charged lipids that are targeted by M1 (Table 6). Asso-
ciation to these lipids explains the appearance of M1 at the intracellular membranes as 
well as the plasma membrane. PI4P was found to be a new potentially specific target of 
M1. This lipid induced different secondary structural changes in M1 compared to PS. Un-
charged lipids could be excluded as direct binding partners for M1.  
 
2. The evaluation of the structural basis for the membrane attachment of M1 was undertaken. 
A single membrane binding domain was not found in M1. Rather the protein showed dual 
binding with its N- and C-terminal domain. 
 
3. The organization of M1 on membranes was examined. It formed flat oligomers with a 
lateral extension on negatively charged lipids containing giant unilamellar vesicles of 
various compositions. Clusters that were made up from a protein which consisted only of 
the N-terminal part of M1 showed loose interaction to the underlying lipids. This interac-
tion had no significant influence on the lateral movement of the lipids. 
 
It is possible to fine tune the current model for influenza virus assembly based on these find-
ings. An interaction of M1 with the spike proteins was shown to mediate the transport of M1 
to the plasma membrane [26,58]. The place where M1 is coupled to the spike proteins is not 
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known. If M1 targets PI4P specifically, M1 is localized at the Golgi apparatus, since PI4P is a 
Golgi marker [175,176]. The initial connection between M1 and the spike proteins could oc-
cur at the Golgi apparatus. Golgi-bound M1 could change its binding partner from PI4P to the 
cytoplasmic tails of HA and NA. From there HA-M1 and NA-M1 heterodimers could be 
transported towards the plasma membrane. Support of this hypothetical pathway could be 
obtained by affinity binding assays like surface plasmon resonance. This method was already 
used with M1 to reveal its affinity for phosphatidylserine containing membranes [179]. A 
PI4P-containing membrane could be used as a binding matrix for M1. The addition of LUVs 
with reconstituted HA or perhaps only the cytoplasmic tail of HA could release M1 from the 
membrane matrix. The fact that M1 builds oligomers on surfaces might make these experi-
ments difficult to accomplish.  
The analysis of GUV-bound M1 showed for the first time a lateral multi-molecular oligomeri-
zation of M1 on a membrane that mimics the plasma membrane in a simple way. M1 oli-
gomerization was not triggered by interaction with other viral proteins. This was proposed in 
a recent review [115]. It happened spontaneously. This ability of M1 to organize spontane-
ously to higher molecular structures gives the molecular basis for the viral assembly at the 
budding site. The incorporation of the cytoplasmic tails of HA and NA into the clustered M1 
would fix HA and NA at the budding site. The transmembrane domains of both proteins are 
incorporated into lipid raft microdomains which are enriched in sphingomyelin and choles-
terol. When M1 cross-links HA and NA, it would also cross-link the protein-associated mi-
crodomains at the plasma membrane. The clustering of HA on the plasma membrane of 
mammalian cells was examined by FLIM-FRET and FRAP in detail [52,53]. The impact of 
M1 could be analyzed by coexpression of M1 in this context. 
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Appendix 
Supplementary Figure 1 Coomassie stained non-reducing SDS-gel for M1m, NM1, NM1m, and CM1. The ex-
pressed proteins were consistent in the molecular mass to the predicted values. 
 
 
Supplementary Figure 2 FM-labeled M1 mutants. (A) Coomassie stained reducing gel. (B) FM fluorescence of 
the labeled proteins. A small amount of unbound FM ran at the bottom line 
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Supplementary Figure 3 (A) Amino acid sequence of the C-terminal part of M1. Basic amino acids are depicted 
in blue letters. Amino acids used for the calculation of helix properties are underlined. Predicted helix formation 
in CM1 in green. Confidence values for the prediction in light blue. The prediction was performed according to 
[158]. (B) Calculation of α-helix properties for the two α-helices with high confidence values. A hydrophobic 
interface was proposed in both helices (MVMAAV in H1; LMLYL in H2). The calculation was performed on 
http://heliquest.ipmc.cnrs.fr according to [196]. 
 
 
Supplementary Figure 4 Fluorescence intensity of C6-NBD-PS on GUVs. The intensity of the middle panel de-
picts the C6-NBD-PS intensity in false colors. The first column shows a DOPC/DOPS-GUV with NM1-TMR. 
The second and the third column represent DOPC/DOPS-GUVs with bound NM1 clusters. GUVs were produced 
by electroswelling. TMR-NM1 was added as mentioned earlier (see Figure 28). Images were recorded after 30 
min incubation. The temperature in the microscopy room was set to 24 °C. 
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